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The failure to eliminate self-reactive T cells is a prerequisite for autoimmunity. 
To escape thymic deletion, autoreactive T cell receptors (TCRs) may form relatively 
unstable complexes with self-peptide–MHC. These TCRs adopt suboptimal docking 
topologies in striking contrast to the classical topology of anti-microbial TCRs. 
Alternatively, escape can occur by weak binding between self-peptides and MHC. We 
determined the structure of a human autoimmune TCR (MS2-3C8) bound to a self-
peptide from myelin basic protein (MBP) and the multiple sclerosis-associated MHC 
molecule HLA-DR4. MS2-3C8 is encephalitogenic in humanized transgenic mice. 
The structure showed loose accommodation of MBP in the HLA-DR4 binding groove, 
accounting for its low affinity. By contrast, MS2-3C8 binds MBP–DR4 as tightly as 
the most avid anti-microbial TCRs. Structurally, MS2-3C8 engages self-antigen via a 
docking mode that closely resembles the optimal topology of anti-microbial TCRs, 
  
but is distinct from that of other autoreactive TCRs. Combined with a unique CDR3β 
conformation, this docking mode compensates for the weak binding of MBP to HLA-
DR4 by maximizing interactions between MS2-3C8 and MBP. Thus, the MS2-3C8–
MBP–DR4 complex reveals the basis for an alternative strategy whereby autoreactive 
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Our immune system is specialized for defense against invading microorganisms. 
Defense is mediated by different types of white blood cells which intervene at different 
stages of the immune response. Cells of the innate immune system represent the first line 
of defense, quickly responding to infections. However, the limited variability of innate 
immune receptors leads to limited defenses that may be overwhelmed by pathogens. 
Adaptive immunity is conveyed by B and T lymphocytes. Through gene rearrangements, 
these lymphocytes are able to achieve virtually unlimited variations for recognizing 
almost all pathogens. Once triggered, the adaptive immune response is specific, robust, 
and determined to win the battle against invading microbes. Meanwhile, all immune 
defenses are tightly regulated and are underpinned by mechanisms to distinguish self and 
foreign. However, as seen in autoimmune diseases, such as type 1 diabetes (T1D), 
multiple sclerosis (MS), and systemic lupus erythematosus (SLE), the host immune 
system may lose its ability to discriminate self from foreign and begin to attack normal 
tissues. In most of these diseases, damages are mediated by self-targeting CD4
+




1.1 T cell-mediated immunity  
Adaptive immunity can be divided into B lymphocyte-mediated humoral immunity 
and T lymphocyte-mediated cellular immunity. Each T lymphocyte expresses one 
clonotypic antigen receptor, the T cell receptor (TCR), which recognizes peptide antigens 
that are processed and presented by antigen-presenting cells (APCs). A mature T 
lymphocyte also expresses either the CD8 or CD4 co-receptor molecule, which binds to 
major histocompatibility complex (MHC) class I or class II molecules, respectively, on 
the APC surface. CD8
+
 T cells respond to peptides presented by MHC class I molecules, 
whereas CD4
+
 T cells recognize peptides presented by class II molecules. T cell 
activation also requires the co-stimulatory molecules B7 and CD28, which are expressed 
on the APC and T cell, respectively. Upon encountering a specific antigen, the engaged 
TCR delivers an activation signal to the T cell, with help from co-receptor and co-
stimulatory molecules. An activated T cell will then exert its immune functions, 
depending on what type of T cell it is: CD8
+
 T cells are cytotoxic cells that directly 
terminate infected target cells by releasing cytotoxins; CD4
+
 T cells usually become T 
helper cells that secret cytokines to assist the function of other immune cells, such as 
macrophages, B cells, and CD8
+
 T cells. 
 
1.2 How does a T cell recognize its ligand? 
1.2.1 Structure of the ligands 
Two classes of MHC molecules are associated with antigenic peptides from different 
sources due to different antigen-processing pathways. MHC class I molecules bind to 
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peptides derived from cytosolic antigens, whereas class II molecules bind to peptides 
derived from endocytosed extracellular proteins. The peptide-binding site of MHC is 
shaped like a groove, with six β-strands forming the floor and two -helices forming the 
walls (Figure 1.1). Depending on the topology of the groove, the lengths of the bound 
peptides are different for MHC class I and class II molecules. Because the binding groove 
of MHC class I is closed at both ends (Figure 1.1-B), it is restricted to binding peptides 9 
residues in length. By contrast, the open-ended groove of MHC class II (Figure 1.1-D) 
molecules can accommodate peptides of 12–25 residues (Stern and Wiley, 1994).  
The compositions of MHC molecules are distinct for the two classes, although both 
are non-disulfide-linked heterodimers. Class I molecules are composed of a heavy chain 
and β2-microglobulin. The extracellular part of the heavy chain has three 
immunoglobulin-like (Ig) domains, designated α1, α2 and α3. The peptide-binding 
groove is formed by the α1 and α2 domains. β2-microglobulin is an invariant single Ig 
like domain (Figure 1.1-A). Therefore, the peptide specificity of a class I molecule is 
solely determined by the heavy chain. Class II molecules, by contrast, are composed of α 
and β chains, two polypeptides of approximately equal length. Each chain has two Ig-like 
domains: α1 and α2, or β1 and β2. Peptide binding is determined by both chains, since 
the groove is formed by the α1 and β1 domains (Figure 1.1-C).  
In human, MHC proteins are known as human leukocyte antigens (HLA), including 
HLA-A, HLA-B and HLA-C for class I, and HLA-DP, HLA-DQ and HLA-DR for class 
II. There are multiple alleles at the gene loci encoding these proteins. Some of the loci, 
such as HLA-A, -B, -C and -DRB1, have hundreds of alleles in human populations 
(Lefranc et al., 2009).  Such  high  degree of  polymorphism  makes  it  possible for MHC 
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Figure 1.1: Structures of MHC class I and class II molecules.  
(A) Ribbon diagram of a human MHC class I molecule, HLA-A2, bound to a 9-residue viral 
peptide, Tax (PDB code: 1DUZ) (Khan et al., 2000). The heavy chain of HLA-A2 (shown in 
gray) contains three domains. β2-microglobulin is yellow and the peptide is magenta. 
(B) Top view of the HLA-A2–Tax complex. The surface of HLA-A2 is gray, with the bound Tax 
peptide (magenta) shown as a stick model. The two ends of the peptide-binding groove are 
closed, which constrains the peptide length for MHC class I molecules.  
(C) Ribbon diagram of a human MHC class II molecule, HLA-DR4, bound to a 13-residue 
hemaglutinin (HA) peptide (PDB code: 1J8H) (Hennecke and Wiley, 2002). Both the α (gray) 
and β (yellow) chains of HLA-DR4 contain two domains.  
(D) Top view of the HLA-DR4–HA complex. Compared to MHC class I, both ends of the 
peptide-binding groove in MHC class II molecules are open, which allows peptides of varying 
length to bind.  
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molecules to present peptides of various sequences, which is critical for shaping 
diversified T cell repertoires to combat pathogens (Messaoudi et al., 2002).  
 
1.2.2 Structure of T cell receptors  
 
 
Figure 1.2 Structural resemblance between a TCR and the Fab fragment of an Ig. 
(A) Ribbon diagram of the first TCR structure, mouse TCR 2C (PDB code: 1TCR) (Garcia et al., 
1996). The α- and β-chains are blue and green, respectively. The individual domains and six 
CDR loops are labeled.  
(B) Structure of the Fab fragment of an anti-HIV antibody, b12 (PDB code: 2NY7) (Zhou et al., 
2007). The heavy chain is cyan and the light chain is green. The individual domains and six 




T cell activation is initiated by the binding of a TCR to its cognate peptide–MHC 
(pMHC) ligand(s). Crystal structures of all TCRs in the Protein Data Bank (PDB) have 
revealed that the extracellular portion of a TCR is very similar to the Fab moiety of 
antibodies (Figure 1.2). The TCR molecule is composed of disulfide-linked - and -
chains. Each chain has two Ig domains, a variable (V) domain and a constant (C) domain. 
During T cell development, genes encoding the full-length - and -chains are generated 
through somatic rearrangement of variable (V), diversity (D), joining (J) and C gene 
segments (Figure 1.3). For the human -chain, the Vα domain is formed by one of 54 
TRAV (Vα) genes and one of 61 TRAJ (Jα) genes (Lefranc et al., 2009). The Vβ domain 
of the human -chain is formed by one of 67 TRBV (Vβ) genes, one of 2 TRBD (Dβ) 
segments, and one of 14 TRBJ (Jβ) segments (Lefranc et al., 2009). The C gene segments 
encode the constant domains, the connecting peptides and transmembrane polypeptides 
that follow the V domains. The ligand-binding site of a TCR consists of six 
complementarity-determining regions (CDRs), which are three hypervariable loops from 
each V domain corresponding to the CDRs of an antibody Fab fragment (Figure 1.2). The 
CDR1 and CDR2 loops are entirely encoded by the V segments, whereas the CDR3 loops 
are formed by connecting the V segments to either J (in Vα) or D and J (in Vβ) segments. 
V(D)J rearrangement is mediated by two lymphoid-specific proteins, RAG-1 and RAG-2, 
as well as several non-lymphoid-specific DNA repair enzymes (Swanson, 2004). 
Moreover, addition and deletion of nucleotides take place at the joining sites, which 
further increase the size of the TCR repertoire (Matthews and Oettinger, 2009; Tillman et 
al., 2004). The random pairing of - and -chains also contributes to repertoire diversity 
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Figure 1.3 Gene rearrangements of TCR α- and β-chains. 
TCR gene rearrangements is DNA recombination events that in a clonotypic manner. After the V 
regions are formed by selected V(D)J segments, rearranged genes transcribe into mRNA followed 
by splicing to connect the C regions with the V regions. It is notable that α- and β-gene 
rearrangements take place at different stages of T cell development. TCR β-gene rearrangement 
occurs in the “double-negative” stage when each TCR β chain pairs with an invariant α-chain 
(pre-Tα). TCR α-gene rearrangement occurs in a later “double-positive” stage. Expressed α-




(Krangel, 2009). Through these mechanisms, a mature TCR repertoire can ultimately 
achieve a diversity of 10
14 
 receptors (Marrack and Kappler, 1988). 
Collectively, the overall assembly process of TCR genes resembles that of antibody 
genes, and both can achieve highly diverse receptor repertoires. However, antigen 
recognition by TCRs differs from that by antibodies in a critical way: unlike antibodies, 
which recognize an unlimited variety of antigens,  TCRs have evolved to interact only 
with MHC molecules bearing peptide antigens. The mechanism for this inherent bias is 
yet not clear. 
 
1.2.3 MHC Restriction 
In the early 1970’s, Rolf Zinkernagel and Peter Doherty discovered that the specific 
activities of cytotoxic T cells were associated with compatible MHC backgrounds of 
mouse strains (Doherty and Zinkernagel, 1975; Hafler et al., 1996; Steinman, 1996a; 
Steinman, 1996b). In other words, T cell recognition is MHC-restricted. Although MHC 
restriction appears quite obvious today when we have clearly understood the structural 
basis of T cell recognition (i.e. binding of a TCR to its peptide–MHC ligand), this was a 
remarkable finding at that time. The discovery gave important information for solving the 
puzzle of whether there were two types of TCRs, one for MHC and one for antigen, or 
one TCR for both (Janeway and Jason, 1980). When the crystal structure of the MHC 
class I molecule HLA-A2 was reported in 1987, the strong electron density between the 
α1 and α2 domains led to the conclusion that antigen was bound there as a processed 
peptide, immediately suggesting that MHC and antigen molecules are simultaneously 
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recognized by a single TCR (Bjorkman et al., 1987). This conclusion was validated in 
1996 by the structure of TCR A6 bound to HLA-A2 and a viral peptide (Garboczi et al., 
1996). It was in the same year that Zinkernagel and Doherty were awarded the Nobel 
Prize in Medicine for their discovery of MHC restriction. 
 
1.3 Positive and negative selection 
As the basis for T cell recognition, MHC restriction is essential for all aspects of cell-
mediated immunity, including shaping the peripheral T cell repertoire during lymphocyte 
development, as well as specifically targeting pathogens in the periphery. At the end of 
the “double positive” stage of T cell development, each T cell expresses a fully-




 (Anderson and Jenkinson, 2001). 
However, the T cell repertoire is not prepared for properly exerting immune functions 
until all T cells in the thymus pass positive and negative selection. The main purpose of 
positive selection is to ensure that all T cells recognize antigens in a self-MHC-restricted 
fashion, while negative selection serves to establish central tolerance, which prevents 
autoreactive T cells from entering the periphery (Starr et al., 2003). In these selection 
processes, MHCs expressed on the medulla epithelial cells are bound to self-peptides. 
Thymic selection is primarily based on the affinities or avidities of TCRs for self-pMHC 
ligands. Whereas low-affinity ligands promote positive selection, strong interactions 
between TCR and self-pMHC induce negative selection. As a result, those T cells with no 
response to self-pMHCs, or with too strong responses, are eliminated, which generates a 
self-MHC-restricted and self-peptide-tolerant T cell repertoire that is prepared for 
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immune defense in the periphery (Huseby et al., 2008; Huseby et al., 2005). 
However, the “quality control” process in the thymus is not perfect, as evidenced by 
the presence of T cells in the periphery reactive with autoantigens. Normally, these T 
cells are under the leash of peripheral regulatory machineries, but they may still evade 
peripheral surveillance and begin to attack self, resulting in autoimmune diseases, such as 
multiple sclerosis. Of the many factors that may initiate T cell-mediated autoimmunity, 
the existence of self-reactive T cells in the periphery is a prerequisite. Here, we are 
particularly interested in how autoimmune T cells escape negative selection. Through 
structural investigations, we hope to learn whether autoimmune TCRs share structural 
features that enable them to evade thymic deletion.  
 
1.4 Multiple sclerosis and autoimmunity 
Multiple sclerosis (MS) is a human autoimmune disease of the central nervous 
system (CNS). Approximately 400,000 people in the US and 2.5 million people 
worldwide are affected by MS (NMSS, 2010). Because most of the patients are between 
the ages of 20 and 50, MS is considered as socioeconomically important. Based on 
disease progression, MS can be generally divided into two categories: relapsing-remitting 
MS (85–90%) and primary progressive MS (10–15%) (Sospedra and Martin, 2005). 
More detailed examinations of patients’ symptoms should give a more thorough 
classification of the disease, which highlights the complexity of MS pathology 
(Lucchinetti et al., 1996). 
It is believed that the major player in MS are autoreactive CD4+ T lymphocytes that 
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attack and damage the myelin sheath around nerve axons (Figure 1.4) (Steinman, 1996b). 
The subsequent inflammation and destruction of myelin impairs the electrical 
conductivity of nerves and may eventually cause disability or even death. The myelin 
components that have been identified as autoantigens, including myelin basic protein 
(MBP), myelin oligodendrocyte glycoprotein (MOG) and myelin proteolipid protein 
(PLP), are present mostly in the CNS, except that MBP is also expressed in peripheral 
myelin tissues (Bruno et al., 2002; Seamons et al., 2003). To become pathogenic, an 
autoreactive T cell must first be activated under particular conditions. For example, 
fdafefeffefeafeafagdgeafegaggageae 
 
Figure 1.4 Multiple sclerosis is a CD4
+
 T cell-mediated autoimmune disease of the CNS.  
T cells that are activated in the periphery are able to migrate across the blood-brain barrier 
(BBB). In other cases, they may enter the CNS through breaches in the BBB. Autoreactive T 
cells can either be activated by myelin antigens or by cross-reactive microbial peptides. 




altered cytokine production may break the immune balance by lowering the threshold for 
activating autoimmune cells (Banchereau et al., 2004). Alternatively, autoreactive T cells 
may accidentally cross-react with a foreign antigen, such as a microbial peptide, 
consequently triggering activation (Harkiolaki et al., 2009). Unlike other autoimmune 
diseases, autoantigens in MS, being sequestered behind the blood-brain barrier (BBB), 
are not accessible to the immune system under normal conditions (Williams and Hickey, 
1995). However, activated T cells are found at inflammatory sites in the CNS, indicating 
that they are able to penetrate the BBB (Hickey, 1999). It is believed that the integrity of 
the BBB is compromised in the early development of MS, which exposes central nervous 
tissues to autoaggressive lymphocytes (Kermode et al., 1990).  
Polymorphic MHC genes are known to be the greatest genetic risk factor for MS, as 
well as other autoimmune diseases (Sospedra and Martin, 2005). Certain MHC alleles 
have the ability to present particular self-antigens, which help promote positive selection, 
but avoid negative selection of autoreactive T cells. It is known that different ethnic 
populations have different genetic backgrounds that relate to predisposition to 
autoimmune diseases. For MS, the MHC haplotype HLA-DR2 confers susceptibility to 
the disease in Caucasians of nothern European descent (Barcellos et al., 2003), whereas 
HLA-DR4 confers susceptibility in those of southern Mediterranean populations 
(Marrosu et al., 1988). Most HLA-DR2-positive patients display the relapsing-remitting 
type of MS, whereas HLA-DR4 is more associated with primary progressive MS. How 
the MHC genotype contributes to the disease heterogeneity of MS is not understood. In 
addition to MS, HLA-DR4 is also a strong genetic risk factor for type 1 diabetes and 
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rheumatoid arthritis (Deighton et al., 1989; She, 1996).  
To study the pathogenesis of MS, a mouse disease model for this disease, known as 
experimental autoimmune encephalomyelitis (EAE), has been extensively used. EAE can 
be induced by immunization with myelin-derived autoantigens or adoptive transfer of 
pre-activated autoimmune CD4
+
 T cells (Constantinescu et al., 1998; Gold et al., 2006). 
Successful induction of EAE by adoptive transfer of CD4
+
 T cells supports the idea that 
MS is a CD4
+
 T cell-mediated autoimmune disease.  
 
 
1.5 Biophysical and structural studies of MHC class II-
restricted antigen recognition by TCRs 
1.5.1 Peptide binding by MHC class II molecules 
Naturally-processed MHC class II-bound peptides are 10–34 residues long, but the 
core binding sequences usually span nine residues (P1 to P9) (Appella et al., 1995). The 
peptide-binding groove of a class II molecule is formed by the two long helices of both 
chains and six β-strands (Figure 1.1-C). Peptide residues having side chains pointing 
towards the groove are called “anchor residues” (Figure 1.5, labeled residues), whereas 
other residues with side chains protruding out of the groove usually interact with the TCR. 
MHC molecules form pockets or cavities in the peptide-binding site to accommodate 
anchor residues. Peptide selectivity is achieved when a pocket is constructed with allele-
specific polymorphic residues (Sinigaglia and Hammer, 1994). Among all human MHC 
class II gene loci, HLA-DRB1, encoding the  subunit of HLA-DR molecules, is the 
most polymorphic. By contrast, HLA-DRA, encoding the  subunit of HLA-DR, is 
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essentially invariable and can pair with any -chain to form an HLA-DR heterodimer 
(Lefranc et al., 2009). A typical HLA-DR-binding peptide uses residues P1, P4, P6, P7 
and P9 as anchors (Figure 1.5-A). A hydrophobic P1 residue can be shared by all HLA-
DR molecules (Hammer et al., 1993). It is the most important anchor residue for binding. 
Previous studies showed that replacing hydrophobic P1 residues by residues with polar 
side chains results in complete loss of peptide binding to HLA-DR1, whereas a 
polyalanine analog with a tyrosine as the P1 anchor retained its binding ability (Hammer 
et al., 1994). The P1 and P4 pockets are less polymorphic than the P6, P7 and P9 pockets. 
The fine specificity of peptide binding is modulated mostly by the P6, P7 and P9 anchor 
residues, as high levels of polymorphism are observed at these pockets that define the 
sizes and chemical compositions of corresponding anchor residues (Chelvanayagam, 
1997; Zavala-Ruiz et al., 2003). HLA-DR4 is highly homologous to HLA-DR1 and uses 
similar peptide selection criteria (Hammer et al., 1995). 
Mouse MHC class II I-E molecules are homologous to HLA-DR, whereas I-A 
molecules are homologous to HLA-DQ (Figure 1.6). Thus, the peptide-binding motifs for  
I-E molecules are similar those of HLA-DR molecules, but different from the binding 
motifs of I-A or HLA-DQ molecules (Raddrizzani et al., 1997). Alignments of I-A-
binding peptides indicated higher variability at P1, indicating that this position is not as 
conserved or critical as it is for binding to HLA-DR or I-E molecules. Instead, for HLA-
DQ/I-A, residues P4 and P9 serve as primary anchors (Figure 1.5-B), while pockets P1, 
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Figure 1.5 Peptide binding motifs of the class II molecules HLA-DR and HLA-DQ.  
(A) Structure of HLA-DR1 bound to hemaglutinin peptide HA 308-316 (PDB code: 2G9H) 
(Fernandez et al., 2006). (B) Structure of HLA-DQ8 bound to a gluten peptide (PDB code: 
2NNA) (Henderson et al., 2007). The peptide-binding sites of the two MHC molecules are 




Sequence alignment of α-chains 
 10        20        30        40        50        60            
           ....|....|....|....|....|....|....|....|....|....|....|....| 
HLA-DR-α  IKEEHVIIQAEFYLNPDQSGEFMFDFDGDEIFHVDMAKKETVWRLEEFGRFASFEAQGAL  
I-Ek-α    .....T........L..KR................IE.S..I......AK..........  
HLA-DQ8-α  VADHVASYGVNL.QSYGP..QYSHE.....E.Y..LER.....Q.PL.R..RR.DP.F..  
I-Ak-α     ---HVGSYGITV.QS.GDI.QYT.E.....L.Y..LD......M.P..AQLRR..P..G.  
                   70        80        90       100       110       120         
           ....|....|....|....|....|....|....|....|....|....|....|....| 
HLA-DR-α   ANIAVDKANLEIMTKRSNYTPITNVPPEVTVLTNSPVELREPNVLICFIDKFTPPVVNVT  
I-Ek-α     ..........DV.KE...N..DA..A......SR...N.G...I........S.......  
HLA-DQ8-α  T....L.H..N.VI....S.AA..EV.....FSK...T.GQ..T...LV.NIF.....I.  
I-Ak-α     Q...TG.H....L.....S..A..EA.QA..FPK...L.GQ..T....V.NIF...I.I.  
                  130       140       150       160       170       180      
           ....|....|....|....|....|....|....|....|....|....|....|....| 
HLA-DR-α   WLRNGKPVTTGVSETVFLPREDHLFRKFHYLPFLPSTEDVYDCRVEHWGLDEPLLKQWEF  
I-Ek-α     .....R...E..........D..........T.....D.F...E.D....E...R.T...  
HLA-DQ8-α  ..S..HS..E.....S..SKS..S.F.IS..T....ADEI...K............H..P  
I-Ak-α     ....S.S..D..Y..S.FVNR.YS.H.LS..T.I..DD.I...K......E..V..H..P  
 
Sequence alignment of β-chains 
 10        20        30        40        50        60            
           ....|....|....|....|....|....|....|....|....|....|....|....| 
HLA-DR1-β  GDTRPRFLWQLKFECHFFNGTERVRLLERCIYNQEESVRFDSDVGEYRAVTELGRPDAEY  
I-Ek-β     -GS..W..EYC.S....Y...Q.....V.YF..L..NL........F............N  
HLA-DQ8-β  R.SPED.VY.F.GM.Y.T........VT.Y...R..YA.......V.....P..P.A...  
I-Ak-β     ----GS.VH.FQPF.Y.T...Q.I..VI.Y...R..Y.......................  
                   70        80        90       100       110       120         
           ....|....|....|....|....|....|....|....|....|....|....|....| 
HLA-DR1-β  WNSQKDLLEQRRAAVDTYCRHNYG-VGESFTVQRRVEPKVTVYPSKTQPLQHHNLLVCSV  
I-Ek-β     ....PEF...K..E...V.....E-IFDN.L.P.....T.....T.....E.........  
HLA-DQ8-β  .....EV..RT..EL..V.....Q-LELRT.L......T..IS..R.EA.N.........  
I-Ak-β     ..--.QY..RT..EL..V.....EKTETPTSLR.LEQ.S.VISL.R.EA.N...T.....  
                  130       140       150       160       170       180      
           ....|....|....|....|....|....|....|....|....|....|....|....| 
HLA-DR1-β  SGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPS  
I-Ek-β     .D....N.........K...T.I.....VR................Q.............  
HLA-DQ8-β  TD...AQ.K......D...TT.....P..R.......I.....MT.QR.D....H.....  
I-Ak-β     TD...AK.K..........TV..S..Q..R.......V.....MT..R......H.....  
                   190  
           ....|....|... 
HLA-DR1-β  VTSPLTVEWRARS  
I-Ek-β     L.D.V....K.Q.  
HLA-DQ8-β  LQN.II.....Q.  
I-Ak-β     L...I......--  
  
Figure 1.6 Amino acid sequence alignment of human and mouse MHC alleles. 
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1.5.2 Structural properties of TCR reactive to foreign peptides 
Since the first ternary structure of a TCR–pMHC complex was determined 14 years 
ago (Garboczi et al., 1996), structural studies have focused on TCRs specific for 
microbial and other foreign peptides. Collectively, these studies have revealed similar 
binding topologies for TCRs (Rudolph et al., 2002; Rudolph et al., 2006). For a typical 
class II-restricted TCR complex (Figure 1.7-A), with the peptide-binding groove facing 
up, the TCR molecule sits on top of the pMHC ligand, with its center over the central 
residue of the peptide at P5 (Figure 1.7-C). A typical interaction involves three CDR 
loops contacting areas around the N-terminal half of the peptide and three CDR loops 
contacting areas around the C-terminal half. Thus, a “crossing angle” (see definition in 
legends of Figure 1.7) is defined to give a quantitative description of the TCR binding 
orientation (Reinherz et al., 1999). All anti-foreign TCRs bind with a crossing angle in 
the diagonal to orthogonal range (Figure 1.7-B). As a result, the MHC α-helices are 
mostly contacted by the CDR1 and CDR2 loops, while contacts to the peptide are largely 
mediated by CDR3 loops. With such a docking orientation, the TCR maximizes its 
contact surface with pMHC. It is also possible that the binding of co-receptors and other 
accessory molecules to form a signaling assembly may require such a docking orientation. 
Such conserved binding topologies by anti-foreign TCRs are hardwired by the biased 
interaction between TCR and MHC. As discussed above, the antigen-binding sites of 
TCRs and antibodies are closely related in terms of their sequence and structural 




Figure 1.7 Structure of an anti-microbial TCR–pMHC complex.  
(A) Overview of the complex of TCR HA1.7 and HLA-DR4 bound to a viral peptide, HA 306–
318 (PDB code: 1J8H) (Hennecke and Wiley, 2002). (B) Top view of the structure. The Cα and 
Cβ domains of HA1.7, as well as the α2 and β2 domains of HLA-DR4, are removed for clarity. 
The P5 residue of HA is shown as a red sphere on the magenta backbone of HA. The two black 
spheres mark the centers of mass of the Vα and Vβ domains. A black dash line connecting the 
two dots forms an angle with a line drawn by linking the Cα atoms of the P1 and P9 residues of 
HA. This angle is defined as the “crossing angle” of TCR docking. (C) Side view of the 






are restricted to binding MHC molecules or the MHC-like molecule CD1. Conserved 
interactions between MHC and the germline-encoded CDR1 or CDR2 loops of TCR are 
found in almost all class I or class II complexes (Marrack et al., 2008). However, whether 
these phenomena are the result of co-evolution between MHC and TCR, or the 
consequence of positive selection during lymphocyte development, is still under 
considerable discussion (Collins and Riddle, 2008; Garcia et al., 2009; Marrack et al., 
2008). 
 
1.5.3 Biophysical characterizations of MHC class II-restricted 
recognition 
As discussed previously, positive and negative selections are primarily based on 
TCR–pMHC affinities. In addition, affinities are a major determinant of T cell activation. 
Although TCRs share structural features with the Fab fragments of antibodies, TCRs 
have much weaker affinities for their peptide–MHC ligands. For instance, the affinity of 
an Fab for a protein antigen can exceed 10
-9
 M; by contrast, a typical TCR has an affinity 
in the range of 1–50 µM (Cole et al., 2007; Rudolph et al., 2006). In addition to affinity, 
the half-life or the dissociation rate constant, koff, of an interaction may also play a role in 
T cell responses, which appears to be particularly important as it dictates how long a T 
cell “dwells” on a pMHC surface (Lyons et al., 1996; Stone et al., 2009). During thymic 
selection, the entire pre-mature T cell repertoire is scanned by self-peptide–MHC 
complexes to prevent further development of autoreactive clones. To make the process 
efficient, the time each T cell clone remains ligated to an individual pMHC should be 
relatively short, but still long enough for signal transductions to occur. As a result, the 
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half-lives of peripheral TCR–pMHC interactions also fall within a narrow window of 
0.2–30 seconds (Cole et al., 2007; Rudolph et al., 2006).  
Extensive measurements of TCR binding affinities and kinetics have been carried out 
to understand the biophysical properties of the interaction between TCRs and their 
cognate pMHC ligands. The binding affinity of a TCR is usually in the low micromolar 
range, which is comparable to the affinities of other molecular interactions at the 
lymphocyte cell surface. Yet, compared to the binding of other lymphocyte cell–cell 
recognition molecules, TCR–pMHC interactions usually have slower kinetics (van der 
Merwe and Davis, 2003). For instance, the association rate constant (kon) of a TCR–

















 (van der Merwe and Davis, 2003). This may indicate that the TCR–
pMHC interaction is a rate-control step for triggering a T cell signaling cascade. In 
addition, based on an average 20-fold longer half-life, the TCR–pMHC complex, once 
formed, is more stable than other most cellular interactions, which may be crucial for 
specifically amplifying signals during T cell activation (van der Merwe and Davis, 2003). 
 
1.5.4 Altered binding topology of TCRs specific for self-antigens 
Since negative selection prevents T cells with strong responses to self-antigens from 
entering the periphery, an autoimmune T cell may escape negative selection using certain 
strategies that compromise the overall stability of the signaling complex. Assuming the 
accessory molecules are invariant, this instability can be introduced by an unstable TCR–
pMHC ternary complex. Recent biophysical and structural studies have shown that 
autoimmune TCRs adopt suboptimal binding modes for self-pMHC, resulting in reduced 
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affinities and altered binding topologies (Nicholson et al., 2005; Wucherpfennig et al., 
2010). 
The two human autoimmune complexes that currently have known structures are 
TCR Ob.1A12 bound to MBP 85-99–HLA-DR2b (Hahn et al., 2005) and TCR 3A6 
bound to MBP 89-101–HLA-DR2a (Li et al., 2005). Both TCRs were isolated from MS 
patients and could induce EAE in humanized mice transgenic for the TCR and HLA-
DR2b or HLA-DR2a. Because the previously known class I- and class II- TCR–pMHC 
complexes had presented similar structural features, the complex structures of these two 
autoimmune TCRs (Figure 1.8) have drawn considerable attention as they bind pMHC in 
ways that differ significantly from the classical mode of anti-foreign TCRs (Figure 1.7). 
The Ob.1A12 TCR engages pMHC with a crossing angle of 105º, which is outside the 
diagonal-to-orthogonal range. Moreover, both Ob.1A12 and 3A6 bind to the N-terminal, 
instead of the central, portion of the MBP peptides. In addition, both TCRs are shifted 
toward the β1 helix, instead of being equally balanced between the two helices. These 
atypical topologies are also associated with low TCR affinities for self-pMHC ligands. 
Thus, Ob.1A12 binds to MBP–DR2b with KD = 81 µM (Cole et al., 2007), whereas 3A6 
binds to MBP–DR2a with even lower affinity (>200 µM) (Li et al., 2005). Studies of 
these two TCRs suggested that such suboptimal binding modes might be a common 
strategy used by autoimmune TCRs to escape negative selection.  
Additionally, the aberrant docking angle of Ob.1A12 may represent a different 
mechanism for thymic escape. For T cell activation, the interaction between TCR and 






Figure 1.8 Altered binding topologies of autoimmune TCRs.  
(A) Top view of the complex structure of TCR 3A6 bound to MBP 89-101–HLA-DR2a;  
(B) Top view of the complex structure of Ob.1A12 bound to MBP 85-99–HLA-DR2b; 
(C) Side view of the interaction between MBP and the CDR3 loops of TCR 3A6; 
(D) Side view of the interaction between MBP and the CDR3 loops of TCR Ob.1A12. 
Coloring and labeling are the same as in Figure 1.7. 
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involves co-receptors (CD4 or CD8) and other accessory molecules for recruitment of 
downstream signaling molecules such as the tyrosine kinase Lck. The engagement of 
accessory molecules should be optimal when TCR and pMHC are oriented in a 
conventional binding mode. The overall stability of this assembly should be able to 
exceed the activation threshold in order to elicit an immune response in the periphery. A 
similar threshold may apply to negative selection in the thymus, where stable assemblies 
with self-peptides induce programmed cell death to eliminate self-reactive T cells, 
whereas unstable assemblies permit survival. Although the affinity of Ob.1A12 is higher 
than that of 3A6, its 105
o
 crossing angle may affect ligation of the CD4 co-receptor, 
which is likely to allow the maturation of T cells bearing this TCR, since a sufficiently 
stable signaling complex may not form. 
 
1.6 Autoimmune TCR MS2-3C8 recognizes MBP presented 
by HLA-DR4 
1.6.1 MBP 111-129 is an immunodominant self-peptide in HLA-
DRB1*0401 MS patients 
Myelin basic protein (MBP) is the major protein component of the myelin sheath and 
a target for nerve tissue damage. Autoreactive T cells recognize various epitopes of MBP 
associated with different MHC molecules. In Caucasians, the MHC class II allele HLA-
DRB1*1501 is the most common genetic risk factor for MS (Hillert and Olerup, 1993). 
MBP 81-99, recognized in the context of this allele in MS patients, has been the most 
investigated immunodominant epitope. However, therapies based on these studies may 
not apply to other ethnic groups with different genetic backgrounds. As mentioned above, 
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HLA-DR4 confers susceptibility to MS in Caucasians of Mediterranean origin. 
Examinations of MS patients carrying the HLA-DR4 (B1*0401) allele suggested a 
distinct immunodominant MBP epitope (Muraro et al., 1997). MBP exists as different 
isoforms resulting from alternative mRNA splicing. Among them, the classical form, 18.5 
kDa MBP, is predominant in the nervous system, and is also expressed in immune organs, 
such as thymus (Pribyl et al., 1993). MBP 111–129, contained in this 18.5-kDa isoform, 
was found to be the immunodominant self-peptide in the context of HLA-DR4 (Muraro 
et al., 1997).  
In one study, MBP-specific T cell lines (TCLs) were established from 12 subjects, all 
carrying the B1*0401 allele. A set of overlapping 19-mer peptides covering the full 18.5-
kDa length of MBP was used for testing the fine peptide specificity of these TCLs. It was 
found that 65% of a total 275 TCLs responded to MBP 111–129, whereas the next most 
frequent peptide, MBP 81-99, only activated 6.6% of TCLs, indicating that MBP 111–129 
dominates the MBP-specific T cell response in HLA-DR4-carrying subjects. Further 
investigations revealed a limited usage of TCR rearrangements in these MBP 111–129-
specific T cells. Sequence analysis showed that the TCRA4.1 and TCRB2.1 or TCRB7.1 
genes are overrepresented in the T cell pool. Characteristic amino acids found in the 
CDR3 sequences indicated that only TCLs with certain gene rearrangements could 
respond to MBP 111–129, further suggesting a restricted T cell repertoire for MBP 111–
129/HLA-DR4 (Muraro et al., 1997). 
Muraro et al. (1997) also performed peptide competition assay to measure the 
relative binding affinity of each MBP peptide for HLA-DR4. Surprisingly, the 
immunodominant MBP 111–129 epitope is such a weak binder that it binds DR4 
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approximately 75-fold less tightly than the influenza virus hemagglutinin epitope HA 
307–319, a microbial peptide known to bind well to DR4. By contrast, MBP 81–99 binds 
efficiently to HLA-DR4 as well as HLA-DR2 alleles. Unlike MBP 111–129, MBP 81–99 
elicits a diverse T cell repertoire. The affinity of the self-peptide for MHC determines the 
stability of the self-pMHC complex, as well as the overall stability of the TCR–pMHC 
complex, which may therefore affect the outcome of thymic selection. An inverse 
relationship between the diversity of a TCR repertoire and the affinity of the antigenic 
peptide for MHC has been further documented recently: Baumgartner et al. (2010) 
demonstrated in mice that peptides with high affinity for MHC class II recruit a more 
diversified CD4
+
 T cell repertoire, whereas peptides with low affinity shape a more 
restricted TCR repertoire, but with higher functional TCR avidity. It is important to 
mention that the dose of administrated antigens also impacts TCR repertoire diversity, as 
low doses of high-affinty peptides also lead to limited usage of TCRs with higher 
avidities (Baumgartner et al., 2010). 
 
 
1.6.2 MS2-3C8 is an MS-related TCR specific for MBP 111–129 in the 
context of HLA-DR4 
MBP-specific TCLs were established from the peripheral blood of a DRB*0401-
positive MS patient at two time points over two years apart. Of these TCLs, 80–90% 
responded to MBP 111–129 in the context of HLA-DR4. Sequence analysis showed that 
these MBP 111–129-specific TCLs resulted from clonal expansion of a single T cell clone 
(TCC), designated MS2-3C8. The repeated isolation and overrepresentation of MS2-3C8 
in the patient’s peripheral blood strongly suggested the involvement of this particular 
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TCC in MS disease pathogenesis. To assess the relevance of MS2-3C8 to disease 
incidence and progression, Quandt et al. (2004) generated humanized mice transgenic for 
MS2-3C8 and HLA-DR4. CD4
+
 MS2-3C8 T cells were then isolated from the spleens of 
these mice. The pathogenic potential of TCR MS2-3C8 was demonstrated by the ability 
of these transgenic cells to induce EAE in HLA-DR4-transgenic mice, which displayed 
both clinical phenotypes of EAE and cellular inflammation in the CNS (Kawamura et al., 
2008; Quandt et al., 2004).  
 In order to become pathogenic in the periphery, an autoimmune TCR must first 
escape the clonal deletion. MS2-3C8 recognizes MBP 111–129, which is a low-affinity 
epitope for HLA-DR4. It has been shown that the establishment of self-tolerance may be 
incomplete with a low-affinity epitope, whereas high-affinity epitopes (e.g. HLA-DR2-
binding MBP 81–99) can efficiently induce T cell tolerance (Kawamura et al., 2008). 
However, the molecular basis for autoreactive TCR recognition of low-affinity epitopes is 
not clear. For MS2-3C8, we were interested in how this particular autoimmune TCR 
recognizes MBP 111-129 presented by HLA-DR4. Does this TCR indeed have a higher 
affinity than other autoreactive TCRs, as suggested by Baumgartner et al. (2010)? 
Structurally, does TCR MS2-3C8 follow the altered binding patterns seen in the other two 
autoimmune TCRs, 3A6 and Ob.1A12? If MS2-3C8 is a high-affinity TCR, it may not 
necessarily bind in the same way as 3A6 and Ob.1A12, the two low-affinity TCRs. 
Instead, it is more likely that MS2-3C8 engages its ligand as other high-affinity TCRs, 
namely anti-microbial TCRs. By characterizing the binding features of MS2-3C8, we 















There are different strategies available to acquire relatively large quantities of 
proteins for the purpose of crystallization. In order to obtain more homogeneous proteins, 
we chose to produce MS2-3C8 and MBP–HLA-DR4 using in vitro folding method. Since 
MBP 111–129 is a weak peptide for HLA-DR4, we covalently linked the peptide to the 
MHC to stabilize the pMHC complex. Initially, the yield of in vitro folding was not 
satisfactory. Efforts were then taken to optimize the folding conditions. The yields were 




Macromolecule crystallography requires high-purity protein samples for obtaining 
crystals suitable for X-ray diffraction analyses. Initial crystallization trials usually require 
at least a milligram of purified protein. Therefore, producing sufficient amounts of 
biologically active proteins is the first “bottleneck” for the determination of protein 
structures. For biophysical and structural studies of the interaction between autoimmune 
TCR MS2-3C8 and HLA-DR4 bearing the MBP 111–129 self-peptide, we produced these 
two proteins in soluble form. 
The production of MHC molecules loaded with homogenous peptides has been much 
studied, as pMHC complexes are not only used for structural determination and 
biophysical characterization, but also in immunological assays, such as 
immunohistochemical staining or flow cytometric sorting of antigen-specific T cells. 
Compared to research on class I-oriented CD8
+
 T cell responses, studies of CD4
+
 T cells 
are more limited. One of the major reasons for this disparity is that class II molecules are 
technically more difficult to produce. Recombinant MHC class I molecules are typically 
folded in vitro from bacterial inclusion bodies with high yields. In some cases, MHC 
class II can be produced using similar methods (Arimilli et al., 1995; Frayser et al., 1999). 
However, yields are generally much lower than for MHC class I. Therefore, class II 
molecules are mostly produced using eukaryotic expression systems, including 
mammalian, yeast, and insect cells. Various approaches have been applied to increase the 
stability and expression level of MHC class II molecules. The two polypeptides of an 
MHC class II heterodimer are not covalently linked by disulfide bonds. To enhance their 
29 
association and therefore stabilize the heterodimer, Kalandadze et al. (1996) added a 
Fos/Jun leucine zipper pair to the C-termini of the - and β-chains of HLA-DR2. The 
soluble protein was initially secreted by yeast strain Pichia pastoris at a relatively low 
level of 0.4 mg/L (Kalandadze et al., 1996). To prepare proteins for structural studies, 
Smith et al. (1998) switched to a baculovirus insect cell expression system for better 
expression. The leucine zipper was enzymatically cleaved before crystallization. In 
another case, HLA-DR4, when produced in a baculovirus system, gave better yields 
when co-expressed with a chaperone protein, calreticulin, to assist protein folding in the 
endoplasmic reticulum (Fourneau et al., 2004). Stably transfected Drosophila S2 cells are 
another popular source for MHC class II production for X-ray crystallographic studies 
(Amicosante et al., 2001; Hennecke et al., 2000). 
The structure of HLA-DR4 was previously determined from proteins that were 
produced in either Drosophila S2 cells (Dessen et al., 1997; Hennecke and Wiley, 2002) 
or baculovirus-infected Hi5 cells (Bolin et al., 2000).  The binding groove of MHC 
molecules expressed in insect cells is partially occupied by endogenous peptides (Hill et 
al., 1994; Scheirle et al., 1992). The unresolved side-chain conformation of the human 
collagen II (hCII) peptide in the DR4 structure (2SEB) is probably a result of 
heterogeneity in peptide binding (Dessen et al., 1997). Such heterogeneity would be 
problematic for co-crystallizing pMHC with TCR, since TCR only recognizes a specific 
peptide. Because MBP 111–129 binds weakly to HLA-DR4, it is difficult to achieve 
homogeneity by simply loading the peptide into the MHC molecule. To assure 
homogeneous association, the MBP peptide can be covalently attached to N-terminus of 
DR4 β-chain via a 16-amino acid linker (GGGGSLVPRGSGGGGS). This strategy, first 
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introduced by Kozono et al. (1994) (Figure 2.1), simplifies production by omitting the 
peptide loading step. More importantly, it effectively stabilized the peptide-bound MHC 
class II molecule, which was produced by baculovirus-infected Sf9 cells (Kozono et al., 
1994).  
 
Figure 2.1 MHC class II I-E
k
 engineered with a covalently bound peptide.  
Structure of I-E
k
 bound to hemoglobin peptide Hb 64–76 (magenta) covalently linked to the N-
terminus of the β-chain (green) via a 16-mer peptide linker (yellow) (PDB code: 1IEA) 
(Fremont et al., 1996). The peptide linker is visible in the crystal structure because of its 
interaction with another I-E
k
 molecule in the asymmetric unit. 
 
TCR molecules can be produced similarly to MHC molecules, either in insect cells 
or by in vitro folding from bacterial inclusion bodies. Several methods have been 
developed to engineer soluble and stable TCR proteins. First, a single-chain form of TCR 
(scTCR) was designed by connecting the two V domains with a 25-mer linker (Schodin 
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et al., 1996). However, because scTCRs lack C domains, they are not suitable for most 
biological assays. The low success rate of soluble scTCR expression is another reason 
that a more general method is needed for TCR production.  
In another approach, the ectodomains of the TCR α- and β-chains are covalently 
linked by a disulfide bond formed by a pair of cysteine residues at the C-termini of the C 
domains. However, in vitro folding of TCRs with the C-terminal disulfide often gives 
satisfactory yields, while TCRs lacking this disulfide may be unstable. To overcome these 
problems, Boutler et al. (2003) introduced cysteine mutations in the middle of the C 
domains in order to create an artificial interchain disulfide link. In this way, soluble TCR 
proteins were obtained in relatively high yields; moreover, these engineered TCRs behave 
biochemically the same as native TCRs. A large number of TCR structures solved today 
include this artificial disulfide bond.  
Thus, there are a number of options for producing recombinant TCR and MHC 
molecules. However, because each TCR or MHC is a unique protein, the best strategies 
to produce MS2-3C8 and MBP–HLA-DR4 had to be found empirically. 
 
2.2 Results 
2.2.1 Production of MBP-bound HLA-DR4 
  MBP 111–129 (LSRFSWGAEGQRPGFGYGG) is specifically recognized by the T 
cell clone MS2-3C8 in an HLA-DR4-restricted manner (Muraro et al., 1997; Quandt et 
al., 2004). These authors also determined that MBP 116–123 (WGAEGQRP) contains the 
minimal epitope for T cell stimulation, in which Trp116 serves as the P1 anchor residue. 
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Thus, we used residues 114–126 of MBP as a 13-mer core sequence for binding to HLA-
DR4. Since this self-peptide is a low-affinity binder for HLA-DR4, it was possible that it 
would not stably associate with the MHC molecule. Therefore, we designed a peptide-
linked construct to obtain MBP-bound HLA-DR4 proteins, in addition to a non-linked 
construct.  
 
i. Non-peptide-linked HLA-DR4 is produced but is not stable 
As a first attempt, chemically synthesized MBP 114–126 was added to an in vitro 
folding solution to incorporate the peptide into the binding groove of HLA-DR4 during 
the folding process. We achieved a reasonable yield of about 0.5 mg/L protein after 
purification. However, the purified MBP–HLA-DR4 did not maintain its integrity, 
probably due to dissociation of the heterodimer. In addition, non-linked MBP–HLA-DR4 
failed to bind TCR MS2-3C8 in a surface plasmon resonance (SPR) assay, which 
indicated that the protein had lost its biological activity (data not shown). The behavior of 
this non-linked form of MBP–HLA-DR4 suggests that the affinity of the bound peptide is 
positively correlated with the overall stability of the MHC molecules (Dedier et al., 2000; 
Saito et al., 2004).  
 
 ii. Peptide-linked HLA-DR4 is stable but with low yield  
To enhance the association of MBP 114–126 with HLA-DR4 and thereby stabilize 
the pMHC complex, we attached the peptide to the N-terminus of the β-chain via a 16-
mer flexible linker (SGGGSLVPRGSGGGGS) (Figure 2.2). The engineered protein was 
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produced by in vitro folding similarly to non-linked form, but without the addition of 
synthetic MBP peptide. However, the yield of purified protein was too low for 
crystallographic studies. Nevertheless, this material was for testing binding to TCR MS2-
3C8 by SPR, which revealed that the peptide-linked form of MBP–HLA-DR4 was 
biologically active (see Chapter 3).  
 
 -----> NdeI <-------------MBP(114-126)------------><-------- 
 gatatacatatgtttagttggggtgcagaaggtcaacgtccaggttttggttctggtggt 




   G  S  L  V  P  R  G  S  G  G  G  G  S  G  D  T  R  P  R  F  
 
Figure 2.2 Sequence of HLA-DRB1*0401 with MBP 114–126 covalently attached to its 
N-terminus via a 16-aa linker. 
 
To improve the yield of in vitro folding, a folding matrix was designed based on our 
initial folding condition and available commercial folding kits (Table 2.1). Small scale 
foldings (1 ml) were set up for each condition of the folding matrix, which was sampled 
at two different time points, 3 and 7 days. Properly folded MBP–HLA-DR4 species was 
detected by ELISA using a mouse anti-HLA-DR monoclonal antibody (L243). The data 
showed that the folding yield was strongly affected by pH, that salt is a strong inhibitor of 
MBP–HLA-DR4 folding, and that varying the redox ratio did produce dramatic effects 
(Table 2.1, Figure 2.3). Moreover, longer folding time were necessary to achieve better 
yields. For large-scale production, the folding time was extended to a minimum of 2 
weeks. This gave yields of 0.1-0.2 mg purified protein per liter of folding mixture, 
following gel filtration and ion exchange chromatography (Figure 2.4). 
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1.1 0 0 0 20 2 0.2 10 8.2
1.2 0.4 0 0 20 2 0.4 5 8.2
1.3 0.8 0 0 20 1 1 1 8.2
1.4 0 0.5 0 20 2 0.2 10 8.2
1.5 0 0.5 0 20 2 0.4 5 8.2
1.6 0 0.5 0 20 1 1 1 8.2
1.7 0 1 0 20 2 0.2 10 8.2
1.8 0 1 0 20 2 0.4 5 8.2
1.9 0 1 0 20 1 1 1 8.2
2.1 0 0 30 0 3 0.3 10 7.5
2.2 0 0 30 0 3 0.9 3.3 7.5
2.3 0 0 30 0 2 1.2 1.7 7.5
2.4 0 0 30 0 3 0.3 10 8
2.5 0 0 30 0 3 0.9 3.3 8
2.6 0 0 30 0 2 1.2 1.7 8
2.7 0 0 30 0 3 0.3 10 8.5
2.8 0 0 30 0 3 0.9 3.3 8.5
2.9 0 0 30 0 2 1.2 1.7 8.5
3.1 0 0 30 0 3 0.3 10 7.5
3.2 0 0 30 0 3 0.9 3.3 7.5
3.3 0 0 30 0 2 1.2 1.7 7.5
3.4 0 0 30 0 3 0.3 10 8
3.5 0 0 30 0 3 0.9 3.3 8
3.6 0 0 30 0 2 1.2 1.7 8
3.7 0 0 30 0 3 0.3 10 8.5
3.8 0 0 30 0 3 0.9 3.3 8.5
3.9 0 0 30 0 2 1.2 1.7 8.5
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Figure 2.3 Folding conditions for MBP–HLA-DR4. 
Folding yields of MBP–HLA-DR4 were analyzed for each condition by ELISA and scored with 
arbitrary numbers of 0 to 10 based on HLA-DR1 positive controls. 0 indicates blank, and 10 
means saturation. All 27 conditions were tested on day 3, whereas only the first 18 conditions 




Figure 2.4 Purification profile of MBP–HLA-DR4.  
(A) Size exclusion chromatography of MBP–HLA-DR4 using a Superdex-200 column. The 
green arrow indicates the fraction containing the folded protein. 






















2.2.2 Production of TCR MS2-3C8 
The MBP-specific TCR, MS2-3C8, was also produced by in vitro folding with either 
the native or the artificial disulfide bridge. Although the construct contauining the 
artificial disulfide gave better yields than the native form, it was less stable and less 
amenable to crystallization. Thus, all subsequent work on MS2-3C8 used only the native 
form, which had a yield of about 1 mg per liter of folding mixture. Figure 2.5 shows 
typical chromatograms of MS2-3C8 by size exclusion column and anion exchange 
columns, from which this TCR was obtained at >95% purity. Analytical 
ultracentrifugation analysis of purified MS2-3C8 showed a peak with a sedimentation 
coefficient of 3.8 S, corresponding to the folded TCR heterodimer (Figure 2.6). Good 
binding activities of the folded molecules were demonstrated in SPR assays (see Chapter 
3).   
 
Figure 2.5 Protein purification profile of TCR MS2-3C8.  
(A) Size exclusion chrmotagraphy of MS2-3C8 using a Superdex-200 column.  




Figure 2.6 Analytical ultracentrifugation analysis of purified TCR MS2-3C8. 
The top panel shows raw sedimentation velocity scans collected for purified MS2-3C8 at 0.4 
mg/mL, overlayed with the best-fit curves obtained from data analysis. The residuals of the fit 
are shown below. The bottom panel shows the sedimentation coefficient distribution for TCR 
MS2-3C8. Apart from a small background peak, the single peak at 3.8 S confirms the 
homogeneity of the MS2-3C8 sample. 
 
2.3 Discussion 
Although there are numerous examples of successful production of MHC and TCR 
molecules by insect cell expression, we preferentially produced our proteins by in vitro 
folding from bacterial inclusion bodies. Basically, there are two non-economical reasons 
we prefer this approach. First, MHC and TCR are both glycoproteins. When expressed in 
insect cells, glycosylation will introduce heterogeneity, which can potentially interfere 
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with crystal packing during crystallization. Second, solubilized inclusion bodies used for 
in vitro folding, although denatured, are usually very pure. Therefore, in vitro-folded 
proteins are generally not fused with any purification tags. This effectively eliminates any 
risk to crystallization that might be caused by a tag.   
One possible reason why in vitro folding of MBP–HLA-DR4 has such a low yield is 
the unusually weak binding of the MBP self-peptide. It has been reported that the affinity 
of the MHC molecule for the bound peptide correlates with the thermal stability of the 
pMHC complex (Saito et al., 2004). The non-linked MBP–HLA-DR4 quickly dissociated 
after purification, unless excess peptide was added, which is consistent with the peptide-
dependent stability of MHC molecules. The MBP-linked HLA-DR4, albeit difficult to 
produce, is a stable molecule that can be employed for biophysical and structural analyses. 
However, the peptide-linking strategy may not guarantee pMHC stability in the case of a 
weaker peptide binder.  Mouse MBP 1–11 is another low affinity peptide, which binds to 
the mouse MHC class II molecule, I-A
u
, with an even lower affinity than MBP 111–129 
binds HLA-DR4 (Fugger et al., 1996). To determine the crystal structure and binding 
kinetics of the MBP–I-A
u
 complex, a high-affinity variant (K4Y) of MBP 1–11 was used 
to connect with the β-chain because I-A
u
 was not sufficiently stabilized by attaching 
wild-type MBP 1–11 (He et al., 2002). It is fortunate in our case that linking wild-type 
MBP 114–126 was sufficient to stabilize the MBP–HLA-DR4 complex; otherwise, we 
would have faced the risk that high-affinity peptide analog may not retain the structural 
or biological properties of the wild type peptide. 
During the process of in vitro folding, different factors modulate the balance between 
aggregation and refolding of a denatured protein. Identifying conditions that favor folding 
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over aggregation sometimes requires extensive trials; alternatively, one may simply 
switch to eukaryotic expression systems. Owing to our own preference for in vitro 
folding, we invested considerable efforts to optimizing the folding conditions. We 
concluded that time is an critical parameter for folding HLA-DR4, which indicates that 
the folding process is particularly slow and that it is difficult to reach equilibrium. The 
buffer pH seemed to be another parameter that impacted the rate and yield of HLA-DR4 
refolding. On one hand, pH interacts with and controls the redox environment of folding 
(Khan et al., 2000); on the other hand, the stability of HLA-DR4 is also dependent on pH 
(Belmares et al., 2000). By characterizing the effects of each parameter, we were able to 
improve the folding yield of MBP–HLA-DR4, which enabled subsequent 
crystallographic studies. 
MHC class II molecules present antigenic peptides to CD4
+
 T cells and elicit helper 
T cell immune functions. The high demand for recombinant TCR and pMHC class II 
molecules for immunological studies contrasts with their low production yields, which 
hinders research in this area. For example, research on MHC class I-dependent cytotoxic 
T cell functions is far more advanced than that on MHC class II-dependent helper T cell 
functions. Moreover, the Protein Data Bank includes over 400 MHC class I structures, 
whereas less than 80 MHC class II structures have been determined. To date, only 7 
human TCR–pMHC class II structures have been reported, 3 of which are very closely 
related (PDB code: 1ZGL, 1FYT and 1J8H, 1YMM and 2WBJ, 2IAM and 2IAN). To 
identify general mechanisms of CD4
+
 T cell recognition of foreign or self-antigens, it is 














The low affinity of MBP for HLA-DR4 leads to unstable formation of the pMHC 
complex, which permits the escape of TCC MS2-3C8. In order to effectively cause 
autoimmune attacks in the periphery, MS2-3C8 is unlikely to bind to MBP–HLA-DR4 
with a weak affinity. To characterize the binding interaction between MS2-3C8 and 
MBP–DR4, we performed both equilibrium and kinetics assays using SPR method. 
Directional immobilization of MBP-linked HLA-DR4 allows more reliable 
measurements. The affinity values obtained from equilibrium and kinetics assays agree 
with each other. MS2-3C8 binds to MBP–DR4 with a high affinity that represents the 
upper end of the affinity range for class II MHC recognition. Besides, the kinetic values 




The initiation of T cell signaling, which is triggered by the binding of TCR to pMHC 
(Eq. 3.1), is remarkably specific and sensitive. Previous binding measurements indicated 
that the affinity, or the equilibrium constant (KD), of a TCR for its pMHC ligand usually 




 M (Cole et al., 2007; Rudolph et 
al., 2006). Additionally, both kinetic parameters, the dissociation rate constant (koff) and 
the association rate constant (kon) (Eq. 3.1), of a TCR binding reaction also fall within 
narrow ranges. The dissociation rate, or the derived half-life (t½) (Eq. 3.3), reflects how 
long the TCR engages its pMHC ligand.  
 
It has been hotly debated whether the affinity or the half-life is better correlated to T 
cell activation. For example, Lyons et al. (1996) demonstrated that T cell stimulation is 
closely related to TCR affinity. Nevertheless, since differences in TCR affinities mainly 
derive from their koff values (Eq. 3.2), these authors suggested that differential T cell 
responses largely depend on the half-life of the corresponding TCR–pMHC complex 
(Lyons et al., 1996). Kersh et al. (1998) obtained further evidence supporting this view by 
examining TCR–pMHC complexes having similar affinities but disparate half-lives 
(Kersh et al., 1998). However, the conclusion that T cell triggering is solely dependent on 
koff may be pre-mature because no one has tested TCRs having similar off-rates but 
different affinities. The affinity of a TCR reflects the responsiveness of the TCR to a 
TCR + pMHC ⇌ TCR∙pMHC              (Eq. 3.1) 
KD = koff/kon                 (Eq. 3.2) 






certain concentration of its cognate pMHC ligand, which determines how many receptors 
on the T cell are bound to pMHC. The more TCRs bound, the easier it is to attain the 
triggering threshold. The differential activation status of an autoimmune TCR in different 
tissues, such as the thymus and the CNS, relies on its affinity and the variable availability 
of its self-pMHC ligand. 
Surface plasmon resonance (SPR), usually performed using a Biacore instrument, is 
one of the standard techniques used for characterizing the binding interaction between 
TCR and pMHC. Compared to other biophysical methods, such as isothermal titration 
calorimetry (ITC), analytical ultracentrifugation (AUC), and fluorescence stopped-flow, 
SPR has several important advantages for analyzing TCR–pMHC interactions. First, SPR 
can measure both kinetic and thermodynamic parameters, whereas ITC or AUC cannot 
provide kinetic information. Second, SPR consumes much less protein sample. TCR–
pMHC interactions have micromolar KDs. For instance, with an affinity of 10 μM, ITC 
requires at least 10 mg of each binding partner to perform a reliable measurement. By 
contrast, a Biacore experiment needs much less. One species, usually the pMHC ligand, 
is immobilized on a chip surface, which requires only microgram amounts of protein, 
while a total of about a half-milligram of TCR suffices for a binding measurement. This 
is especially important for our measurements of TCR MS2-3C8 binding to MBP–HLA-
DR4, because both proteins, especially MBP–HLA-DR4, are difficult to produce. In 
addition, SPR delivers sensitive and accurate measurements, which is important for 
comparing TCRs displaying a narrow range of binding values.  
43 
 
Figure 3.1 Example of an SPR sensorgram. 
In this experiment, the injection of analyte was started at time 0. Association of the 
analyte to the ligand on the chip surface caused an increase in the resonance signal. 
Injection was stopped at 300 sec, which marked the start of the dissociation phase. The 
association curve is highlighted in green, and the dissociation curve is highlighted in red. 
 
In a typical SPR experiment, one binding partner (e.g. pMHC) is immobilized on a 
biosensor chip surface, when the other binding partner (e.g. TCR) flows over the chip. 
During the association phase (Fig. 3.1), TCR molecules binding to immobilized pMHC 
will cause an increase in SPR signal, which is expressed as response units (RU). During 
the dissociation phase, when only buffer is flowed, the SPR signal decreases. For a 
simple 1:1 binding reaction like that between TCR and pMHC, the association and 
dissociation phases may be described by Eq. 3.4 and Eq. 3.6, respectively. Here, the 
concentration of TCR·pMHC complex, [TCR·pMHC], can be replaced by RU, and the 
total concentration of pMHC, equivalent to the maximal concentration of [TCR·pMHC], 
can be replaced by RUmax (Eq. 3.5 and Eq. 3.7). These two equations are used, 
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respectively, for fitting the association and dissociation curves of a Biacore sensorgram, 
in which the concentration of TCR, [TCR], is inputted by the experimenter, RU and time 
t are two variables, and the two kinetic parameters, koff and kon, as well as RUmax are fitted. 
The affinity, KD, is then calculated according to Eq. 3.2.  
Association: 
   
(Eq. 3.4) 







           
 (Eq. 3.7) 
  Table 3.1 Measurable values of rate constants for biological interactions by Biacore 























Because of instrumental limitations, measurable kinetics of an interaction should not 
be too fast.  For a Biacore biosensor, koff should be smaller than 0.1 s
-1







 (Table 3.1). Outside these ranges, kinetic values will not be 
dRU 
dt 
  k off RU 
d [ TCR  pMHC ] 
dt 
  k off [ TCR  pMHC ] 
dRU 
dt 
 k on [ TCR ]( RU max  RU )  k off RU 
d [ TCR  pMHC ] 
dt 
 k on [ TCR ][ pMHC ]  k off [ TCR  pMHC ] 
45 
accurately fitted. However, it is still possible to obtain affinity values for fast interactions 
using equilibrium analysis. With a series of concentrations of TCR flowing over the 
sensor chip, SPR signals at the plateau of equilibrium are recorded. The equilibrium RU 
and TCR concentration are then used as two variables for fitting the affinity KD using Eq. 
3.8. 
   
     (Eq. 3.8)
 
 
Our interest in measuring the binding of TCR MS2-3C8 MBP–HLA-DR4 was 
aroused primarily by the unusually weak binding of the MBP 111–129 self-peptide for 
HLA-DR4. The two MS-related TCRs of known complex structures, Ob.1A12 and 3A6, 
both displayed very low affinities for their pMHC class II ligands, which facilitated their 
escape from negative selection. In these two cases, the self-peptides bind strongly to 
MHC. In sharp contrast, for TCR MS2-3C8, it is the weak peptide–MHC association that 
may have destabilized the overall TCR–pMHC complex and thus enabled MS2-3C8 T 
cells to avoid thymic deletion. However, in order to become activated in the periphery, 
the T cell needs to form a TCR–pMHC complex that is sufficiently stable to initiate the 
signaling cascade. We hypothesized that triggering would be unlikely to occur if TCR 
MS2-3C8 had an affinity as low as Ob. 1A12 or 3A6. Instead, MS2-3C8 is more likely to 
have an affinity at the high end of the affinity range for TCRs recognizing pMHC class II. 
To test our hypothesis, we determined the affinity of MS2-3C8 as well as its binding 














Figure 3.2 Experimental design for SPR analysis of the interaction between MS2-3C8 
and MBP–HLA-DR4. 
Instead of directly immobilizing MBP–DR4, a biotin acceptor peptide, AviTag, was added to the 
C-terminus of the α-chain for producing biotinylated MBP–DR4. Streptavidin is loaded to 
saturation onto the surface of a CM5 biosensor for capturing biotinylated MBP–DR4. In this 
way, MBP–DR4 molecules are directionally immobilized, which effectively reduces signal 




3.2.1 Immobilization of MBP–HLA-DR4 onto a biosensor chip  
To obtain directional immobilization of MBP–HLA-DR4, we attached a biotin 
acceptor peptide sequence AviTag (Avidity, LLC) to the C-terminus of the α-chain of 
DR4. The fusion protein, MBP–HLA-DR4–AviTag, was produced the same way as 
MBP–HLA-DR4 (see Chapter 2). A CM5 biosensor chip was pre-immobilized with 
streptavidin by amine-coupling. MBP–HLA-DR4, which was biotinylated at the C-
terminal AviTag by biotin protein ligase, was then captured by streptavidin on the chip 
surface (Figure 3.2). Streptavidin was loaded to saturation at over 3000 RU, whereas only 
300 to 400 RU of MBP–DR4 was immobilized, in order to minimize steric hindrance that 
might interfere with the binding of MS2-3C8. 
 
3.2.2 Kinetic and equilibrium measurements of MS2-3C8 binding to 
MBP-DR4 
Different concentrations of MS2-3C8 were flowed over immobilized MBP–HLA-
DR4 for kinetic or equilibrium SPR assays. Kinetic parameters (on- and off-rates) for the 




 and koff = 0.011 s
-1
, corresponding to a dissociation 
constant (KD) of 6.5 μM (Figure 3.3-A). Under equilibrium binding conditions, a KD of 
5.0 μM was obtained (Figure 3.3-B), in close agreement with the KD from kinetic analysis. 
The affinity of MS2-3C8 for its self-antigen is therefore at the high end of the range for 
TCR interactions with peptide–MHC class I or peptide–MHC class II (1 to >100 μM) 
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(Cole et al., 2007; Rudolph et al., 2006; van der Merwe and Davis, 2003). Indeed, MS2-
3C8 binds MBP–DR4 about as tightly as the most avid anti-microbial class I-restricted 
TCRs bind their respective ligands, and considerably more tightly than do anti-microbial 
class II-restricted TCRs (Cole et al., 2007). It also binds far more tightly than do human 
autoimmune TCRs 3A6 and Ob.1A12 (KD > 100 μM) (Appel et al., 2000; Li et al., 2005), 
but similarly to mouse autoimmune TCR 172.10 (6 μM) (Garcia et al., 2001). 
In addition to the usually high affinity, the binding of MS2-3C8 for MBP–DR4 also 
exhibits an unusually slow kinetics. The off-rate value of the interaction (0.011 s
-1
, 
corresponding to a half-life of 69 s) is exceptionally small, compared to those of all other 
TCR–peptide–MHC interactions characterized to date (0.02 to >1 s
-1
) (Cole et al., 2007). 




) relative to 
the on-rates of other TCRs (2 × 10
3






), which may imply conformational 
changes in MS2-3C8 and/or MBP–DR4 during complex formation. It is notable that the 
SPR measurements were conducted using an engineered version of the ligand designed to 
overcome the low affinity of MBP for HLA-DR4. Therefore, the results reveal the 
intrinsic high affinity of MS2-3C8 for MBP–DR4, whereas, in reality, the instability of 
the natural MBP–HLA-DR4 ligand would effectively decrease the half-life of the overall 







Figure 3.3. SPR analysis of the binding of TCR MS2-3C8 to MBP–DR4.  
(A) For kinetic measurements, TCR MS2-3C8 at concentrations of 2.9 M, 5.8 M, 11.5 M, 
23 M and 46 M was injected over immobilized MBP–DR4 (320 RU). Sensograms were 
fitted to a 1:1 binding model to obtain on- and off- rates: kon = 1.7 × 10
3




 and koff = 
0.011 ± 0.0003 s
-1
. KD was calculated as koff/kon. (B) For equilibrium measurements, TCR MS2-
3C8 at concentrations of 1.2 M, 2.4 M, 4.7 M, 9.4 M and 18.8 M was injected over 
immobilized MBP–DR4 (400 RU). Inset shows the fitting curve for equilibrium binding that 




Negative selection in the thymus is based on the functional avidity of T cells for self-
antigens, which is comprehensively determined by: 1) the affinity of TCR for self-
peptide–MHC, 2) the affinity of peptide for MHC, and 3) the availability of and need for 
co-receptors and signaling molecules (Anderton and Wraith, 2002). Assuming the co-
receptor and other signaling molecules are invariable parameters, the notion of 
“functional avidity” includes all factors that affect the stability of the TCR–peptide–MHC 
complex, instead of only the affinity of TCR for pMHC. To be pathogenic, autoreactive T 
cells must meet two competing criteria: they must escape thymic deletion, but 
nevertheless signal with sufficient strength in the target organ to cause autoimmune 
disease. This means that, in the thymus, an autoimmune T cell must behave like an anti-
foreign T cell, with no response to self-antigens, to escape the surveillance machinery of 
the negative selection, whereas, in the periphery, the interaction of the same autoreactive 
T cell with self-antigens must exceed a threshold to result in activation. It can then be 
deduced that the functional avidity of an autoimmune TCR lies between the avidities that 
lead to elimination or survival. 
The relatively low stability of autoimmune complexes can be achieved by low affinity 
of the TCR for self-pMHC or low affinity of the self-peptide for MHC. For example, the 
affinity of autoimmune TCRs Ob.1A12 and 3A6 are lower than for all anti-foreign TCRs, 
which allowed the escape of these two T cell clones from the thymus. The MBP self-
peptides in these two cases are both good binders. Alternatively, the weak affinity of a 
self-peptide for MHC can also facilitate the escape of an autoimmune T cell, such as TCR 
51 
MS2-3C8, studied here. The unusually high affinity as well as the extremely slow off-rate 
of MS2-3C8 suggests that, when the self-peptide is not stably associated with MHC, the 
autoimmune TCR must establish a strong interaction with pMHC in order to be 
successfully activated in the periphery. Notably, the affinity of MS2-3C8 for MBP–DR4 
is at the high end of the affinity range for the peripheral TCR repertoire. 
By examining T cells with high functional avidity for various myelin antigens (MBP, 
proteolipid protein, myelin oligodendrocyte glycoprotein), it was shown that 
immunodominant epitopes in MS patients are clearly biased toward epitopes, such as 
MBP 111–129, that bind HLA-DR molecules with low affinity (Bielekova et al., 2004). 
This negative correlation between immunodominance and strength of HLA-DR binding, 
which concurs with animal studies (Anderton et al., 2001; Goverman, 2009; Vanderlugt 
and Miller, 2002), supports the hypothesis that disease-associated MHC molecules permit 
escape of potentially deleterious high-avidity autoreactive T cells due to their poor 
peptide-binding properties (DiPaolo and Unanue, 2002; Stadinski et al., 2010; Starr et al., 
2003). The system we have chosen exemplifies this concept of immunodominance: MBP 
111–129 is an immunodominant epitope in MS patients that binds very weakly to HLA-
DR4, whereas TCR MS2-3C8 binds MBP–DR4 with as high an affinity (KD = 6.5 μM) as 
TCRs recognizing foreign ligands, and with an even slower off-rate (koff = 0.011 s
-1
). We 
propose that the tight binding of MS2-3C8 to MBP–DR4 overcomes the weak binding of 
MBP to HLA-DR4 to sufficiently stabilize the TCR–peptide–MHC ternary complex, 
thereby explaining the ability of this autoreactive TCR to induce CNS inflammation in 







Structural studies of autoimmune recognition of MBP–





The complex structure of MS2-3C8–MBP–HLA-DR4 was solved to the resolution of 
2.8 Å by X-ray crystallography. The structure showed a loose accommodation of MBP in 
the HLA-DR4 binding groove, accounting for its low affinity. The distinctive 
conformation of the bound MBP peptide marks an altered anchor residue, P7 Arg. Instead 
of residing in the peptide-binding groove, the side chain of P7 Arg makes extensive 
contacts with the TCR. Topologically, MS2-3C8 engages MBP–DR4 via a docking mode 
that closely resembles the optimal topology of anti-microbial TCRs, but is distinct from 
that of two previously-characterized autoimmune TCRs. Conserved contacts were 
observed in the recognition of HLA-DR4 by MS2-3C8 and anti-microbial TCR HA1.7. 
Combined with a unique CDR3β conformation, this docking mode compensates for the 





As discussed in previous chapters, thymic selection is primarily based on the stability 
of a TCR-self-pMHC complex. Any instability in the ternary complex, whether 
introduced by low TCR affinity for self-pMHC or by weak binding of self-peptide to 
MHC, facilitates escape from negative selection. In addition to studying the biophysical 
properties of autoimmune recognition, detailed investigation of the molecular assembly 
of the TCR–self-pMHC complexes may help us understand, at the atomic level, how such 
TCRs avoid thymic deletion, but still retain the ability to productively engage self-
antigens in the periphery (Deng and Mariuzza, 2007; Wucherpfennig et al., 2009). In fact, 
structural studies of autoimmune TCRs bound to self-peptide–MHC ligands have begun 
to reveal some recognition pattern used by autoimmune TCRs. Five structures have been 
reported to date, involving two human TCRs from MS patients (Hahn et al., 2005; Li et 
al., 2005) and three mouse TCRs from the EAE model of MS (Feng et al., 2007; Maynard 
et al., 2005). The human TCRs are Ob.1A12, which recognizes myelin basic protein MBP 
85–99 in the context of HLA-DR2b (Hahn et al., 2005), and 3A6, which recognizes MBP 
89–101 presented by HLA-DR2a (Li et al., 2005). Both Ob.1A12 and 3A6 engage their 
MBP–HLA-DR ligands with docking topologies that differ substantially from the way 
TCRs specific for microbial or other foreign epitopes bind peptide–MHC. Whereas anti-
microbial TCRs typically dock on peptide–MHC in a diagonal orientation over the center 
of the antigenic peptide, Ob.1A12 and 3A6 are displaced toward the N-terminus of MBP 
(Wucherpfennig et al., 2009). This suboptimal binding mode results in fewer specific 
interactions with the self-peptide, which is manifested by the much lower affinities of 
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Ob.1A12 and 3A6 compared to anti-microbial TCRs. The three mouse TCRs (172.10, 





 ligand is structurally defective in that the peptide only partially fills the MHC 
binding groove (He et al., 2002). As a result, these mouse TCRs, like Ob.1A12 and 3A6, 
also exhibit suboptimal interactions with the MBP self-peptide, marked by a paucity of 
specific contacts. Together, these studies suggest that structural alterations, which 
destabilize the TCR–pMHC recognition unit, may enable certain self-reactive T cells to 
escape negative selection, without necessarily compromising their ability to cause 
autoimmune disease (Wucherpfennig et al., 2009). Indeed, mice transgenic for TCR 
Ob.1A12 and HLA-DR2b developed CNS inflammation (Madsen et al., 1999), and 
transfer into mice of T cell clones recognizing MBP–I-A
u
 induced EAE (Goverman, 
2009).  
Despite these advances, the database of autoimmune TCR–pMHC complexes is still 
too limited to describe the properties of autoreactive TCR recognition at the repertoire 
level, or to evaluate the extent to which autoreactive TCRs deviate from the rules 
followed by anti-foreign TCRs (Wucherpfennig et al., 2009). To expand our 
understanding of the structural mechanisms governing self-antigen recognition, we 
determined the structure of a human autoimmune TCR MS2-3C8 in complex with the 
weakly binding self-peptide MBP 114–126 and MS-associated MHC class II molecule 
HLA-DR4.  
Notably, MBP 114–126 represents an immunodominant epitope of MBP in HLA-
DR4-positive MS patients (Muraro et al., 1997; Sospedra and Martin, 2006). Unlike the 
MBP peptides recognized by TCRs Ob.1A12 and 3A6, which bind with high affinity to 
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HLA-DR2 and elicit a diverse TCR repertoire, MBP 111–129 binds weakly to HLA-DR4 
and is recognized by a restricted TCR repertoire. The MBP 111–129-specific T cell clone 
MS2-3C8 was repeatedly isolated from the peripheral blood of a patient with relapsing-
remitting MS over a two-year period (Muraro et al., 1997). In addition, the clonal 
overrepresentation and persistent expansion of MS2-3C8 T cells in this patient suggested 
an involvement in the disease process. The pathogenic potential of TCR MS2-3C8 was 
demonstrated using transgenic mice expressing this autoimmune TCR and HLA-DR4 
(Quandt et al., 2004). These humanized mice readily developed EAE in adoptive transfer 
experiments without antigen administration.  
Through detailed analyses of interfacial contacts between TCR MS2-3C8 and MBP-
DR4, we expected to understand the basis for the weak binding of MBP to HLA-DR4, 
and to explain how this autoreactive TCR compensates for its unstable self-antigen to 




4.2.1 Crystallization of TCR MS2-3C8 bound to MBP–HLA-DR4 
The constructs used for crystallization studies are MBP 114–126-linked HLA-DR4 
and MS2-3C8 with a natural interchain disulfide bridge (see Chapter 2). Both proteins 
were produced by in vitro folding from bacterially expressed inclusion bodies. Initial 
crystallization trials scored a hit using the Emerald Wizard I crystal screen kit (Emerald 
BioSystems, Inc.), which proved to be the MS2-3C8–MBP–HLA-DR4 complex (Figure 
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4.1-A). Small needle-like crystals were found in the drop containing 10% PEG-8000, 0.1 
M imidazole, 0.2 M calcium acetate, pH8.0. After optimization of the crystallization 
conditions, the crystals changed form to small plates. Serial rounds of macro-seeding 
were performed, which increased the size of the plates (Figure 4.1-B). From a crystal of 
dimensions 0.5 × 0.2 × 0.05 mm
3
, a 360˚ dataset to 2.8 Å resolution was collected at 
Brookhaven National Synchrotron Light Source (Upton, NY) (Figure 4.1-C).  
 
Figure 4.1 Crystallization of the complex between MS2-3C8 and MBP–HLA-DR4. 
(A) SDS-PAGE of dissolved crystals showing that they contained both MS2-3C8 and MBP–
DR4. Crystal was washed three times with crystallization solution before being dissolved in 
non-reducing SDS protein sample buffer.  
(B) Microscopic image of optimized crystals of the MS2-3C8–MBP–DR4 complex. The right-
most crystal has a length of about 0.5 mm. 
(C) Diffraction pattern of a crystal of the complex. 
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4.2.2 Structure determination: Data process, molecular replacement 
and structure refinement 
The space group of the crystal was determined as P21212. Each asymmetric unit 
contains two MS2-3C8–MBP–HLA-DR4 complexes. The solvent content of the crystal 
was estimated as 62%. The complete dataset was processed to 2.8 Å, with an overall 
Rmerge of 8.8% (Table 4.1). The completeness values of the dataset at the overall level and 
the last resolution shell are both 100%, which facilitated molecular replacement (MR).  
Known MHC and TCR structures were used as MR search models. Two MBP–DR4 
molecules were immediately found with the coordinates of HA–DR4 (PDB code 1J8H) 
(Hennecke and Wiley, 2002), but only one MS2-3C8 molecule was found using various 
TCRs (1YMM, 3DX9, 1KGC) (Archbold et al., 2009; Hahn et al., 2005; Kjer-Nielsen et 
al., 2002) as search models. A new search model consisting of a complex of MS2-3C8 
and MBP–DR4 was then created by positioning a symmetry mate of the TCR opposite 
one of the found MBP–DR4 molecules. Two complete complexes were then readily 
located by Phaser (Adams et al., 2010).  
Rigid-body and simulated-annealing refinements were conducted using CNS1.2 
(Quandt et al., 2004). Manual model fitting was performed with the program Coot (van 
der Merwe and Davis, 2003). The 16-mer peptide connecting MBP to the HLA-DR4 β 
chain had visible electron density in one of the two complexes and was built accordingly. 
Subsequent refinements of positional and atomic displacement parameters were carried 
out using Phenix-1.5.2 (Adams et al., 2010). Water molecules were added with a distance 
cut-off of 3.4 Å. The interface between TCR and pMHC was unambiguous for each of 
the  two molecules in the asymmetric unit of the crystal  (Figure 4.2-B).  Several loops in  
 
 
   Table 4.1  Data collection and refinement statistics 
    Data collection   
  Space group P21212 
  Resolution (Å) 49.2–2.8 
  Unit cell (Å) a = 102.5, b = 218.4, c = 98.4 
  Unique reflections 55,156 
  Multiplicitya 40.2 (5.0) 
  Completeness (%)a 100 (100) 
  Mean I/σ(I)a 29.7 (5.2) 
  Rmerge (%)a,b 8.8 (35.5) 
    Refinement 
  Resolution range (Å) 49.2–2.8 
  Rwork (%)c 23.9 
  Rfree (%)c 27.9 
  Protein atoms 12,876 
  Water molecules 27 
  
R.m.s. deviations from ideality 
    Bond lengths (Å) 0.010 
    Bond angles (°) 1.339 
  
Ramachandran plot statistics 
    Favored (%) 92.0 
    Allowed (%) 7.8 
    Outliers (%) 0.2 
  
  aValues in parentheses correspond to the highest resolution shell (2.80–2.90). 
    bRmerge(I) = (Σ|I(i)-<I(h)>|/ΣI(i)), where I(i) is the ith observation of the intensity of the hkl 
reflection and <I> is the mean intensity from multiple measurements of the hkl reflection. 





the MHC α2β2 and TCR CαCβ modules lacked electron density; however, these 
disordered regions are distant from the interface. Further refinement was conducted with 
non-crystallographic symmetry (NCS) restraints, interspersed with manual density map 
fitting. The final Rwork and Rfree values are 23.9% and 27.9%, respectively (Table 4.1). 
 
4.2.3 Overview of the MS2-3C8–MBP–DR4 complex  
 
Figure 4.2 Structure of the MS2-3C8–MBP–HLA-DR4 complex. 
 (A) Side view of the MS2-3C8–MBP–DR4 complex (ribbon diagram), including the 16-mer 
peptide linking MBP to the HLA-DR4 -chain. TCR -chain, blue; TCR -chain, green; MHC 
-chain, gray; MHC -chain, yellow; MBP peptide (stick representation), magenta; linker 
peptide, orange.  
(B) Electron density in the interface of the MS2-3C8–MBP–DR4 complex. Density from the 
final 2Fo – Fc map at 2.8 Ǻ resolution is contoured at 1.  
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The two complexes in the asymmetric unit are in close similarity, except that the 16-
mer peptide linking MBP to the N-terminus of the HLA-DR4 β chain exhibited clear 
electron density in only one of the two complexes (Figure 4.2-A), probably due to crystal 
contacts with the Cβ domain of a neighboring complex molecule (Figure 4.3); no density 
could be detected for the linker peptide in the other complex, indicating flexibility. The 
root-mean-squared (r.m.s.) deviation in α-carbon positions for the TCR VαVβ and MHC 
α1β1 modules, including the MBP peptide, is 0.22 Å for the two complexes in the 
asymmetric unit. Because there is no significant difference, the following description of 
TCR–pMHC interactions applies to both complex molecules.  
Compared to anti-microbial TCRs such as HA-specific TCR HA1.7 (Hennecke and 
Wiley, 2002), which typically dock over the central portion of the foreign peptide and 
interact symmetrically with the MHC α1 and β1 α-helices (Figure 4.4-A), the 
autoimmune TCRs Ob.1A12 and 3A6 (Hahn et al., 2005; Li et al., 2005) display 
substantially altered binding geometries, in which the TCR is shifted toward the N-
terminus of the self-peptide and toward the MHC β1 α-helix (Figure 4.4-B, C). In sharp 
contrast to Ob.1A12 and 3A6, MS2-3C8 engages its self-ligand via a binding mode 
which closely resembles that of anti-foreign TCRs (Figure 4.4-D), as exemplified by the 
HA1.7–HA–DR4 complex (Figure 4.4-A). Thus, MS2-3C8 docks symmetrically over 
MBP–DR4 in a canonical diagonal orientation, with a crossing angle of TCR to peptide–
MHC (Reinherz et al., 1999) of 65°, compared with 70° for the HA1.7–HA– DR4 
complex. Moreover, MS2-3C8 is positioned directly over the central P5 residue of MBP, 
rather than being displaced toward the N-terminus of the self-peptide, as in the Ob.1A12– 
MBP–DR2b and 3A6–MBP–DR2a complexes (Figure 4.4, bottom panels).  
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Figure 4.3 Crystal contacts between neighboring complexes. 
Each asymmetric unit contains two MS2-3C8–MBP–DR4 complexes, A and B. Complex B’ is a 
symmetry mate of complex B in a neighboring asymmetric unit. The peptide linker of complex 
A (yellow) makes contacts with the Cβ domain of complex B’ (Cβ’). The bottom large square 
shows an enlarged view of the contact region. The contact residues are drawn in ball-and-stick 
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Figure 4.4 Comparison of human anti-microbial and autoimmune TCR–pMHC class II 
complexes.  
(A) Upper panel: top view of the anti-microbial HA1.7–HA–DR4 complex (PDB code 1J8H) 
(Hennecke and Wiley, 2002). Colors of TCR, MHC and peptide are the same as in Figure 4.3. 
The central P5 residue of the peptide is shown as a red sphere. Bottom panel: position of the 
TCR CDR3 loops over the HA peptide. The peptide is drawn in ball-and-stick representation 
with carbon atoms in pink, oxygen atoms in red, and nitrogen atoms in blue. The CDR loops are 
positioned above the central P5 residue of the peptide.  
(B) The autoimmune Ob1A12–MBP–DR2b complex (1YMM) (Hahn et al., 2005).  
(C) The autoimmune 3A6–MBP–DR2a complex (1ZGL) (Li et al., 2005).  
(D) The autoimmune MS2-3C8–MBP–DR4 complex.  
The comparison shows that autoimmune TCR MS2-3C8, like anti-microbial TCR HA1.7, docks 
symmetrically over pMHC in a central diagonal orientation, whereas autoimmune TCRs 
Ob1A12 and 3A6 are displaced towards the peptide N-terminus and the HLA-DR 1 helix. The 
CDR3 loops of HA1.7 and MS2-3C8 are centered over peptide residue P5; those of Ob.1A12 
and 3A6 are positioned over P2.   
 
The classical docking mode of MS2-3C8 correlates with its high affinity for MBP–
DR4, suggesting that it is an optimal binding mode that enables TCRs to achieve strong 
interactions with antigenic ligands. The MS2-3C8–MBP–DR4 complex also contradicted 
the previous notion that autoimmune TCRs only use altered or suboptimal binding modes 
for recognizing self-antigens.  
The MS2-3C8–MBP–DR4 complex buries a total solvent-accessible surface of 2009 
Å
2
, comparable to that in other MHC class II complexes (Rudolph et al., 2006). The 
buried surface area on Vβ (673 Å
2
, 66%) is nearly twice that on Vα (354 Å
2
, 34%) 
(Figure 4.5-A). Such dominance by Vβ is unusual among TCR–pMHC complexes, in 
which Vα and Vβ typically contribute roughly equal buried surfaces, as in the HA1.7–
HA–DR4 complex (Vα: 47%; Vβ: 53%) (Figure 4.5-B), or in which Vα dominates. 
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Indeed, only two other complexes displaying a similar degree of Vβ dominance as MS2-
3C8–MBP–DR4 have been reported, one involving the HLA-A2-restricted TCR JM22 





Figure 4.5 TCR footprints on the surface of peptide–DR4 ligands. 
(A) Footprint of autoimmune TCR MS2-3C8 on MBP–DR4. The top of the MHC molecule is 
represented as a gray surface; the bound peptide (pink) is shown in stick format under the 
transparent surface. The areas contacted by individual CDR loops are color-coded: CDR1, 
violet; CDR2, purple; CDR3, blue; CDR1, yellow; CDR2, orange; CDR3, green. The 
contact areas of the V domains are contoured: V: yellow; V: red.  
(B) Footprint of anti-microbial TCR HA1.7 on HA–DR4. 
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4.2.4 Altered binding mode of low-affinty self-peptide MBP 114–126 
Based on the complex structure, the primary anchor residues for MBP 114–126 
bound to HLA-DR4 are Trp116 (P1) and Glu119 (P4), which constitute a conserved 
DR4-binding motif as seen in other DR4-binding peptides (Hammer et al., 1995; 
Hammer et al., 1993; Southwood et al., 1998). In the DR4-binding motif, P6 and P7 are 
two secondary anchor residues, both of which should be small nonpolar residues. 
However, in MBP 114–126, P6 and P7 are two large polar residues, Gln and Arg, which 
do not conform to the optimal binding motif for HLA-DR4. Whether these two non-
optimal residues are the source of low-affinity binding of MBP 114–126 was examined 
based on the crystal structure of MBP–DR4. 
The conformation of the MBP peptide was directly compared with those of three 
peptides known to bind HLA-DR4 with high affinity: HA 306–318 (PDB code 1J8H), 
human collagen II peptide 1168–1180 (CII) (PDB code 2SEB) and gp100 (internal 
laboratory communication, not published) (Dessen et al., 1997; Hammer et al., 1995; 
Hennecke and Wiley, 2002). Ignoring side chains, all three peptides display very similar 
main-chain conformations in their corresponding complexes with HLA-DR4, from 
residues P1 to P9 (Figure 4.6). However, MBP diverges from HA, CII and gp100 at 
residues P6 and P7, with an average displacement of 1.9 Å in the position of their α-
carbons, up from the α1β1 platform of HLA-DR4. As a result, MBP sits less deeply in the 
peptide-binding groove, which reduces shape complementarity. The shape correlation 
statistic (Sc) (Lawrence and Colman, 1993) of the MBP–DR4 interface is 0.75, whereas 




Figure 4.6 Structural alignment of HLA-DR4-binding peptides. 
The -carbon backbone of MBP (magenta) was compared with the -carbon backbones of 
hemagglutinin peptide (HA) (green), collagen II peptide (CII) (yellow) and gp100 peptide (blue) 
by superposing the 11 domains of HLA-DR4 in the respective pMHC complexes. The 
peptides are viewed from the side of the 1 helix. MBP diverges from HA, CII and gp100 at 
residues P6 and P7. 
 
In HA, CII and gp100, anchor residues P6 and P7 have short side chains (HA: Thr-
Leu; CII: Ala-Ala; gp100: Thr-Glu), whereas in MBP these residues have long side 
chains (Gln-Arg). The shallower binding of MBP is mainly attributable to these longer 
side chains, but for different reasons. Thus, the side chain of P6 Gln pushes up the MBP 
main chain by pointing directly into the P6 pocket of HLA-DR4 (Figure 4.7), in the same 
direction as the shorter side chain of HA P6 Thr (Figure 4.7). By contrast, the long side 
chain of P7 Arg projects out toward the top of the DR4 β1 helix, rather than into the P7 
pocket, in order to avoid colliding with the α1β1 platform if it pointed in the same 
direction as the side chain of HA P7 Leu (Figure 4.7). This side-chain orientation 
introduces a twist in the main chain of MBP, further elevating the self-peptide from the 
binding groove and weakening its interaction with HLA-DR4. Therefore, compared to 
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other peptide–MHC class II complexes, P7 Arg is not positioned as a typical anchor in 
MBP–DR4. Instead, this residue interacts extensively with TCR (see below).  
 
Figure 4.7 Altered topology of the MBP peptide in the DR4 peptide-binding groove. 
The surface of HLA-DR4 is shown in blue mesh. Both the MBP (magenta) and HA (green) 
peptides are drawn as stick models. Residues P1 to P9 of both peptides are labeled in the same 
color as the peptide. The P6 and P7 residues of MBP do not fit into the HLA-DR4 anchor 
pockets as well as residues P6 and P7 of the HA peptide. 
 
In the HA–HLA-DR4 structure, the HA peptide forms four hydrogen bonds with β-
sheet residues on the floor of the peptide-binding groove (Figure 4.8-B). However, the 
elevation of MBP results in loss of the hydrogen bond between the main-chain nitrogen 
of P7 and the Oη atom of Tyr30β (Figure 4.8-A). In addition, the twist in MBP eliminates 
a hydrogen bond between the main-chain oxygen of P7 and the Nδ2 atom of Asn69α on 
the DR4 α1 helix found in the HA–DR4 complex (Figure 4.8-C,D). The MBP–HLA-DR4 
complex also lacks two side-chain–side-chain hydrogen bonds to Glu55α and Asn62α, 




Figure 4.8 Structural basis for low-affinity binding of MBP 114–126 to HLA-DR4.  
(A, B) Interactions between MBP (A) or HA (B) and the -sheet floor of the HLA-DR4 binding 
groove (gray). The peptides are oriented the same as in Figure 4.7. Hydrogen bonds are shown 
as dotted red lines. The arrow in (B) indicates the hydrogen bond between P7 and Tyr30 in the 
HA–DR4 complex that is absent in the MBP–DR4 complex, where the corresponding atoms are 
too distant (4.9 Å) for hydrogen bond formation (A). 
(C, D) Interactions between MBP (C) or HA (D) and the α1 and β1 helices of HLA-DR4. The 
arrows in (D) indicate three additional hydrogen bonds in the HA–DR4 complex not present in 
the MBP–DR4 complex (C).  
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hydrogen bonds, along with 35 fewer van der Waals contacts between peptide and MHC, 
likely explains the much weaker affinity of MBP than HA for HLA-DR4 (Muraro et al., 
1997).  
 
4.2.5 Conserved interactions between TCR MS2-3C8 and HLA-DR4  
Overall, Vβ makes 57 van der Waals contacts with HLA-DR4, compared to only 19 
by Vα. These contacts are mediated by 11 Vβ and 6 Vα residues and involve 15 MHC 
residues (Table 4.2), of which 12 are contacted by HA1.7 and 10 by 3A6 (Table 4.3). All 
six CDR loops of MS2-3C8 participate in binding HLA-DR4. Although the germline-
encoded CDR1 and CDR2 loops of MS2-3C8 (Vα4.1, Vβ2.1) and HA1.7 (Vα1.2, Vβ3.1) 
differ in both sequence and conformation, they contact similar sites on HLA-DR4, which 
explains the conserved docking orientation. In both the MS2-3C8–MBP–DR4 and 
HA1.7–HA–DR4 complexes, CDR1α and CDR2α interact extensively with DR4 α- 
helical residues Thr77β and His81β (Figure 4.9-A,B). These two residues are conserved 
across all HLA-DR molecules. Besides multiple van der Waals contacts involving 
structurally equivalent TCR residues, these interactions include two hydrogen bonds 
linking CDR1α Ser27 and Thr29 of MS2-3C8 to His81β and Thr77β of HLA-DR4, 
respectively, which are absent in the HA1.7– HA–DR4 complex (Table 4.3). Regarding 
CDR1β and CDR2β, these loops contact Lys39α, Ala64α and Lys67α in both the MS2-
3C8–MBP–DR4 and HA1.7–HA–DR4 structures (Figure 4.9-C,D). Of particular note is a 
conserved salt bridge between CDR2β Glu50 (Asp51 in HA1.7) and Lys67α, which may 
play an important role in anchoring MS2-3C8 and HA1.7 to the MHC α1 helix. By 
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contrast, the overall shift by autoimmune TCR 3A6 toward the N-terminus of the MBP 
self-peptide relative to the central position of MS2-3C8 results in engagement of different 
MHC residues by structurally equivalent CDR1 and CDR2 residues (Table 4.3). This is 
also the case for TCR Ob.1A12, which uses the same Vβ segment (Vβ2.1) as MS2-3C8. 
 
 
Figure 4.9 Conserved contacts between germline-encoded CDR loops and HLA-DR4. 
(A, B) Conserved interactions between the DR4 1 helix and the CDR1/2 loops of MS2-3C8 
(A) or HA1.7 (B). CDR1, violet; CDR2, purple; DR4 β chain, yellow.  
(C, D) Conserved interactions between the DR4 1 helix and the CDR1/2 loops of MS2-3C8 
(C) or HA1.7 (D). CDR1, yellow; CDR2, orange; DR4  chain, gray. Van der Waals contacts 
are shown as dotted black lines, hydrogen bonds as dotted red lines, and salt bridges as solid red 
lines.  
Table 4.2 Interactions between TCR MS2-3C8 and MBP-DR4
Ser 27α Oγ His 81β Nε 1
Gly 28α His 81β 3
Thr 29α O Thr 77β Oγ 3
His 81β 6
CDR2α Leu 50α Thr 77β 1
CDR3α Asn 95α Gly 58α 1
Ala 61α 1
Lys 96α Nη Gln 57α Oε 3
CDR1β Thr 29β Ala 61α 1
Ala 64α 3
Val 65α 6
Thr 30β Ala 61α 1
CDR2β Asn 49β Leu 60α 2
Ala 61α 6
Ala 64α 1
Glu 50β Oε Lys 67α Nη 1
Thr 55β Oγ Lys 39α Nη
Gln 57α 1
CDR3β Arg 95β Ala 61α 1
Gly 97β Val 65α 2
Ser 98β Gly 58α 1
Ala 61α 5
Oγ Asn 62α Oδ 4
Val 65α 1




Asn 100β O Gln 70β Nε 6
Pro 102β Asp 66β 1
CDR1α Ser 27α Ser P-1 3
CDR3α Gly 92α Trp P1 1
Gly P2 3
O Ala P3 N 6
Ala 93α Ser P-1 1
CDR3β Gly 96β Arg P7 4
Pro P8 2
Gly 97β Gln P6 2
Ser 98β N Gln P6 O
Tyr 99β Ala P3 7
Gly P5 1
Asn 100β Arg P7 1
Ser 101 β Oγ Arg P7 Nε 6
Pro 102β Arg P7 1
Hydrogen bonds were calculated using a cut-off distance of 3.4 Å. The cut-off distance for van der Waals 
contacts was 4.0 Å.
Number of van der 


































































































































































































































































































































































































































































































































































































































































































































































4.2.6 The dominant role of CDR3β in self-ligand recognition 
i. Interactions between CDR3 loops and HLA-DR4 
Whereas the CDR3α loop of MS2-3C8 forms only a few contacts with the α1 helix 
of HLA-DR4 (Figure 4.10-A), the CDR3β loop straddles the peptide-binding groove and 
interacts extensively with both the α1 and β1 helices (Figure 4.10-B). These interactions, 
which are mediated by CDR3β residues 95–102, include 35 van der Waals contacts (46% 
of the total to HLADR4) to α1 residues Phe54α, Gly58α, Ala59α, Ala61α, Asn62α and 
Val65α, and to β1 residues Asp66β and Gln70β, in addition to two hydrogen bonds 
(CDR3β Ser98 Oγ–Oδ1 DR4 Asn62α; CDR3β Asn100 O–Nε2 DR4 Gln70β) (Table 4.2). 
Of particular note are CDR3β Gly97 and Ser98, which contact the α1 helix (Figure 4.10-
B). These junctional residues were found to be highly conserved among 23 TCRs 
recognizing MBP–DR4 (Muraro et al., 1997), even for TCRs using different Vβ segments; 
this suggests similar interactions between CDR3β and the DR4 helices to those observed 
for MS2-3C8. Of the total buried surface on HLA-DR4, excluding MBP, CDR1α, CDR2α 
and CDR3α contribute 19%, 4%, and 12%, respectively, compared with 10%, 23%, and 
32%, respectively, for CDR1β, CDR2β and CDR3β. Hence, CDR3β of MS2-3C8 
accounts for more of the binding interface with MHC than any other CDR. The 
dominance of CDR3β in the MS2-3C8–MBP–DR4 complex is further emphasized by 
comparing the number of contacts made by this loop in all known TCR–pMHC class II 




Figure 4.10 Interactions between CDR3 loops and HLA-DR4. 
(A) Interactions between CDR3 and the 1 helix of HLA-DR4. (B) Interactions between 
CDR3 and the 1 and 1 helices of HLA-DR4. CDR3, blue; CDR3, orange; DR4  chain, 
gray; DR4  chain, yellow. Van der Waals contacts are shown as dotted black lines and 
hydrogen bonds as dotted red lines. 
 
ii. Interactions between CDR loops and MBP 114–126 
TCRs specific for foreign peptides presented by MHC class I or class II molecules 
typically utilize four of six CDR loops for peptide recognition: CDR1α, CDR3α, CDR1β 
and CDR3β (Rudolph et al., 2006). By contrast, most autoimmune TCRs contact peptide 
using only CDR3α and CDR3β, due to altered binding topology or to partial occupancy 
of the peptide-binding groove (Wucherpfennig et al., 2009). In this respect, MS2-3C8 is 
clearly more akin to autoimmune than to anti-foreign TCRs, despite its canonical docking 
mode and full occupancy of the peptide-binding groove of HLA-DR4 by MBP. Except 
for some minor contacts between CDR1α Ser27 and P-1 Ser, all interactions between 























































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.11 Interactions between CDR loops and MBP 114-126. 
Contact residues are drawn and labeled. TCR -chain, blue; TCR -chain, green; MBP peptide 
(ball-and-stick representation), magenta. Hydrogen bonds are indicated by dotted red lines.   
 
As shown in Figure 4.11, CDR3α contacts MBP residues P1 to P3, while CDR3β 
contacts residues P3 to P8. In agreement with the crystal structure, these residues 
comprise the minimal epitope recognized by MS2-3C8, as defined by T cell proliferation 
assays (Muraro et al., 1997). The CDR3β loop resembles a horseshoe stepping on the C-
terminal three-quarters of the MBP peptide (Figure 4.11). As a result, the contact 
interface between CDR3β and MBP is large (253 Å
2
) and flat, with good shape 
complementarity. Thus, the shape correlation statistic (Sc) (Lawrence and Colman, 1993) 
for the interface between CDR3β and MBP–DR4 is 0.78, which is significantly higher 
than the Sc for the whole interface (0.65). By comparison, the corresponding Sc values for 
the HA1.7–HA–DR4 complex, which has 6-fold lower affinity than the MS2-3C8–MBP–
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DR4 complex (Cole et al., 2007), are both 0.56. Because the tip of CDR3β is directed 
toward CDR3α rather than the peptide, MS2-3C8 lacks the open pocket between CDR3 
loops found in other TCRs that typically accommodates the side chain of residue P5. In 
MBP, P5 is glycine, whose lack of a side chain nonetheless permits this residue to pack 
against the CDR3β flap sealing off the CDR3 pocket of MS2-3C8 (Figure 4.11). Indeed, 
the interaction of CDR3β with MBP is distinguished by the multiple close contacts made 
by this loop to the main chain of the self-peptide (Figure 4.11). These factors, combined 
with the engagement of both DR4 helices by CDR3β, are probably key to the 
unexpectedly high affinity of MS2-C38 for its self-antigen.  
 
4.2.7 Contribution of P7 Arg to complex stability  
As described above, secondary anchor residue P7 Arg is not situated in the P7 pocket 
of HLA-DR4. Rather, it is sandwiched between the DR4 β1 helix and the CDR3β loop so 
as to interact substantially with both molecules (Figure 4.2-B). The long side chain of P7 
Arg projects over the residues Gln64β, Asp65β and Leu67β of HLA-DR4, thus making 
16 van der Waals contacts and 3 hydrogen bonds. On the other side, P7 Arg alone 
accounts for half (12 of 24) the van der Waals contacts made between CDR3β and MBP, 
as well as a side-chain–side-chain hydrogen bond linking the guanidinium group of P7 
Arg to the Oγ atom of CDR3β Ser101 (Table 4.4; Figure 4.11). Collectively, these 
interactions underscore the importance of P7 Arg to securing complex formation. The 
long side chain of P7 Arg compensates for destabilizing the MBP–DR4 self-ligand, 
which likely enabled MS2-3C8 T cells to escape thymic deletion, by reinforcing the 
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interaction between MBP and TCR, which permitted activation of these autoreactive cells 
in the periphery. We therefore conclude that P7 Arg plays a key role in the autoimmune 
function of MS2-3C8 by playing the dual role of weakening the interaction of MBP with 
HLA-DR4 while strengthening that between MBP and MS2-3C8. 
 
4.3 Discussion 
4.3.1 Correlation between binding affinities and topologies 
Since the structures of the two autoimmune complexes were published in 2005 
(Hahn et al., 2005; Li et al., 2005), both displaying strikingly distinct binding features 
comparing to anti-foreign TCRs, it has been widely assumed that all autoimmune TCRs 
adopt suboptimal binding modes in order to escape negative selection (Deng and 
Mariuzza, 2007; Nicholson et al., 2005; Wucherpfennig et al., 2009). Having now solved 
the structure of the autoimmune MS2-3C8–MBP–HLA-DR4 complex, we have shown 
that  not every autoimmune TCR uses an altered binding mode to engage self-pMHC. 
MS2-3C8 docks onto MBP–DR4 in a way that closely resembles anti-microbial TCRs, 
which sit on the center of the pMHC surface with a diagonal docking angle. The classical 
docking mode of autoimmune TCR MS2-3C8, inconsistent with those of Ob.1A12 and 
3A6, dispels the notion that the altered docking mode is a necessary feature of 
autoimmune TCRs.  
On the other hand, the structure of MS2-3C8 demonstrates that the docking mode is 
correlated with TCR binding affinity. The classical binding mode, as broadly defined by 
anti-microbial TCRs, can be viewed as an optimal strategy for TCRs to engage pMHC, 
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which leads to higher binding affinities. By contrast, the altered binding mode used by 
TCRs Ob.1A12 and 3A6 can be viewed as a suboptimal binding strategy, as manifested 
by their low affinities. Although studies have shown that the TCR repertoire before 
positive selection is biased against pMHC (Blackman et al., 1986; Merkenschlager et al., 
1997; Zerrahn et al., 1997), it is still possible that positive selection may further exclude a 
very small percentage of functionally inactive TCRs that recognize irregular epitopes. 
Considering the structural constraints provided either intrinsically or by positive selection, 
a TCR might achieve high affinity only with a canonical binding mode, which maximizes 
the interaction between TCR and pMHC. Therefore, the binding topology of a particular 
TCR is not directly linked with autoimmunity, but correlates with its binding affinity. 
 
4.3.2 Altered docking mode of TCR vs. altered sitting mode of peptide 
The structure of the MS2-3C8–MBP–DR4 complex revealed why the self-peptide 
binds weakly to HLA-DR4. Compared with peptides that bind HLA-DR4 with high 
affinity, MBP 114-129 resides less deeply in the binding groove, due to suboptimal 
anchor resides at positions P6 and P7. This elevation results in the net loss of several 
hydrogen bonds and numerous van der Waals contacts relative to high-affinity peptide–
DR4 complexes.  
MHC molecules, albeit highly homologous, are basically different proteins with 
respect to peptide binding. Their polymorphic peptide-binding grooves are constructed 
with structural or chemical differences that determine the conformations of bound 
peptides; that is, the peptide conformation is MHC-specific. Therefore, it is not possible 
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to propose a universal peptide-binding mode for all MHCs. The structural alterations we 
observed in the MBP–DR4 complex may only be correlated with the low affinity of MBP 
for DR4, rather being characteristic of other pMHC complexes associated with 
autoimmunity. The structural database of human MHC class II molecules bound to self-
peptides is so far too small for us to draw general conclusions on this issue. 
 
4.3.3 Comparison between two autoimmune TCR MS2-3C8 and 172.10 
172.10 is a mouse MHC class II I-A
u
-restricted TCR that is specific for an acetylated 
N-terminal peptide of mouse MBP, Ac1-11 (Maynard et al., 2005). It was selected from a 
T cell line established from I-A
u
-positive mice immunized with MBP (Urban et al., 1988). 
Thus, TCR 172.10 is autoreactive and responsible for the autoimmune inflammation in 
the central nervous system of mice with EAE. The existence of 172.10 in the periphery 
indicates that this TCR also escaped from negative selection. When encountering the 
burst of administrated MBP, it became activated and started to attack myelin self-tissues 
(Urban et al., 1988). In this regard, 172.10 is a mouse autoimmune TCR.  
There are several features that are shared by TCR MS2-3C8 and 172.10. First, the 
antigenic self-peptide MBP Ac1-11 also has very low affinity for MHC, and is therefore 
unable to form a stable complex with I-A
u
 (Fairchild et al., 1993; Fugger et al., 1996; 
Mason et al., 1995). Second, the TCR repertoire selected against MBP Ac1-11 in the 
background of I-A
u
 showed limited sequence diversity. Similarly, restricted usage of TCR 
V genes was observed in MS patients with HLA-DR4 background. Both systems agree 
with the proposition that low-affinity antigenic peptides are linked with a more restricted 
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TCR repertoire (Baumgartner et al., 2010). The structure of the 172.10–MBP–I-A
u
 
ternary complex (Maynard et al., 2005) showed that 172.10 also used a central docking 
mode for MBP–I-A
u
 and achieved a binding affinity close to that of MS2-3C8 (Garcia et 
al., 2001). 
In spite of the shared features, TCR 172.10 also presents major differences compared 
to MS2-3C8. The MBP–I-A
u
 ligand is unusual in that the N-terminal one-third of the 
binding groove is empty (He et al., 2002). The groove contains only the first seven 
residues of the MBP Ac1–11 peptide, leaving the P1 and P2 pockets of I-A
u
 unoccupied. 
By contrast, the binding groove of HLA-DR4 is completely filled by MBP 114–126, 
although portions of the peptide are loosely accommodated. Thus, TCR 172.10 only 
recognizes six peptide residues (P3 to P8), compared with nine (P-1 to P8) in the case of 
MS2-3C8. Moreover, the interaction of TCR 172.10 with MBP Ac1–11 is characterized 
by a paucity of specific contacts between TCR and peptide (Maynard et al., 2005). 
However, such structural degeneracy is not evident in the interface of MS2-3C8 with 
MBP 114–126, which possesses high shape and chemical complementarity. In addition, 
whereas MS2-3C8 and 172.10 have similar binding affinities, the binding kinetics of 
172.10 is completely opposite to that of MS2-3C8.  In contrast to the slow kinetics of 
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), 172.10 binding to MBP–I-A
u
 has 
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-1
). Differential 
kinetics may mediate different signaling processes and result in different cell fate 
decisions. Indeed, the activation process of 172.10 upon MBP administration is probably 
different from that of MS2-3C8, which was repeatedly isolated from an MS patient. It is 
not very likely that a large amount of MBP is suddenly released into blood at the early 
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stage of MS development. However, how the slow kinetics may contribute to the 
signaling decision of MS2-3C8 T cells in the thymus, and how they may relate to disease 
onset and development are not clear. 
Collectively, in terms of TCR recognition, MS2-3C8 does share a few features with 
TCR 172.10, e.g. low-affinity self-peptide, high affinity TCR binding and canonical 
docking modes. These common features may represent a type of autoimmune TCR 
complementary to the previously characterized autoimmune TCRs Ob.1A12 and 3A6, the 
type represented by low TCR affinity and aberrant docking modes. The MS2-3C8–MBP–
DR4 structure therefore provides a framework for understanding how autoreactive T cells 
can successfully target pathogenic self-epitopes with unfavorable MHC-binding 











T cell-mediated autoimmune diseases, e.g. MS, T1D, etc., are initiated by the 
activation of autoreactive T cells. T cell responses to self-antigens lead to tissue damage. 
Activated CD4
+
 autoreactive T cells can assist cytotoxic T cells and macrophages and 
direct them to target self-tissues. Autoimmune T cells isolated from the periphery blood 
of MS patients specifically recognized the self-antigen MBP and mediated myelin 
destruction in the CNS. Since self-reactive T cell clones are normally deleted during 
thymic development via the mechanism of negative selection, these autoimmune cells are 
not allowed to enter the periphery. However, negative selection is not perfect, insofar as 
some autoimmune T cells escape surveillance. Structural and biophysical studies of the 
antigen receptors on these T cells may provide information on the molecular mechanisms 
underlying escape from thymic deletion.  
Our structure of the MS2-3C8–MBP–HLA-DR4 complex displayed striking 
contrasts to the two known human autoimmune TCR–pMHC complexes. Based on the 
high affinity of TCR MS2-3C8, we propose an alternative mechanism for evading 
negative selection. In the previous model, the TCR binds weakly to self-pMHC, 
preventing formation of a stable self-complex that triggers programmed cell death of the 
T cell. Therefore, the low-affinity T cell survives. In our model, it is weak binding of the 
self-peptide to MHC that compromises the stability of the TCR–pMHC complex and 
allowed escape of MS2-3C8. On the other hand, despite the instability of the TCR–
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pMHC complex, an autoimmune T cell must still be activated under certain conditions in 
the periphery in order to cause disease. This means that the TCR–pMHC complex must 
still possess a certain level of stability. In our case, MS2-3C8 shows high-affinity binding 
to MBP–HLA-DR4, which also has an unusually long half-life. 
Our results dispel the notion that all autoimmune TCRs bind their self-ligands with 
altered binding topologies. Since MS2-3C8 adopts a classical binding mode, the binding 
topology is no longer the sole parameter for assessing autoimmune recognition. Instead, 
binding topology must be assessed in the context of binding affinity. The classical 
binding mode correlates with high-affinity binding, whereas altered binding modes 
correlate with low-affinity binding. Nevertheless, compared to the classical binding mode, 
altered binding topologies may cause more distruption to the effectiveness of negative 
selection. Since T cell activation also depends on the function of co-receptors (CD4 or 
CD8), it is possible that altered co-receptor binding to the TCR–pMHC complex may 
contribute as well to thymic escape of autoimmune T cells. In this scenario, the altered 
binding topology of an autoimmune TCR may affect the ligation state of CD4 or CD8, 
thereby compromising the overall stability of the signaling assembly. To assess this, we 
expect that there exists an autoreactive TCR that uses altered binding topology, but 
maintains an average binding affinity. We expect that our understanding of the 
mechanisms governing self-recognition and escape from negative selection will expand 
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1. List of constructs and E. coli stocks 
 
Name DR2α 
Description Ectodomain of HLA-DRA*0101 
Plasmid pLM1 









Protein MW (kDa) 21.3 
Protein pI 4.8 




Description DR2α with an AviTag attached to its C-terminus 
Plasmid pLM1 










Protein MW (kDa) 23.2 
Protein pI 4.7 




Description Ectodomain of HLA-DRB1*0401 
Plasmid pET-26b (+) 








Protein MW (kDa) 22.6 
Protein pI 6.0 






Description DR4β fused with MBP 114-126 and a 16-mer linker to its N-
terminus 
Plasmid pET-26b (+) 








Protein MW (kDa) 25.3 
Protein pI 6.2 




Description Ectodomain of the α chain of TCR MS2-3C8 
Plasmid pET-22b (+) 










Protein MW (kDa) 22.9 
Protein pI 5.0 




Description Ectodomain of the β chain of TCR MS2-3C8 
Plasmid pET-22b (+) 











Protein MW (kDa) 27.6 
Protein pI 6.1 





Description 3C8α engineered for replacing C-terminal disulfide bond of MS2-
3C8 with an artificial disulfide bond between the constant domains 
Plasmid pET-26b (+) 










Protein MW (kDa) 22.9 
Protein pI 5.0 




Description 3C8β engineered for replacing C-terminal disulfide bond of MS2-
3C8 with an artificial disulfide bond between the constant domains 
Plasmid pET-26b (+) 











Protein MW (kDa) 27.6 
Protein pI 6.1 




2. Molecular cloning 
PCR and subcloning were performed according to Molecular Cloning1 or product 
manuals. The gene encoding extracellular residues Ile1–Ala182 of the HLA-DR4 a chain 
(HLA-DRA*0101) was inserted into the expression vector pLM1. The construct for the 
HLA-DR4 b chain (HLA-DRB1*0401), which residues Gly1–Ser192 of the b chain, was 
cloned into the vector pET-26b(+) (Novagen). MBP-linked DR4 b chain (MBP-DR4b), 
                                                        
1
 Sambrook, J., and D.W. Russell. 2001. Molecular cloning : a laboratory manual. Cold Spring 
Harbor Laboratory Press, Cold Spring Harbor, N.Y. 
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which encoded a fusion protein comprising MBP 114–126 (FSWGAEGQRPGFG) 
connected by a 16-mer peptide linker (SGGGSLVPRGSGGGGS) to the b chain (Figure 
2.2), was cloned into the same vector. For the production of biotinylated HLA-DR 
proteins, a 15-amino acid AviTag (GLNDIFEAQKIEWHE) was added to the C-terminus 
of the a chain with two glycine residues inserted as a spacer. The a and b chains of TCR 
MS2-3C8 (residues 1–206 and 1–245, respectively) were also cloned into pET-26b(+). To 
construct 3C8α-intC and 3C8β-intC, the constant domains of the two chains were 
respectively switched with those of TCR G4α-intC and E8β-intC, two TCR polypeptides 
pre-constructed with the artificial disulfide bond in our lab. The two modified chains 
were cloned into pET-26b(+). All constructs were verified by DNA sequencing before 
being transformed into expression strains BL21(DE3) or BL21(DE3)pLysS (see 
Appendix 1). 
 
3. Freezing bacteria 
A single colony of DH5α or BL21(DE3) strain containing the correct construct was 
inoculated in LB medium containing the correct antibiotics (see Appendix 1). The grown 
bacterial culture was supplemented with 1/4 to 1/5 volume of 50% glycerol (1:1 mixture 
of LB and 100% glycerol) before being stored in -80°C freezer. Overgrowth of the 
bacterial culture should be avoided due to the risk of losing plasmids. 
 
 
4. Growth of E. coli cultures for expression of inclusion bodies 
 
1) Grow overnight pre-culture by inoculating 20 μL frozen BL21(DE3) bacteria stock 
into 120 mL LB medium containing the correct antibiotics (see Appendix 1). Shake 
at 30°C for 12-14 hrs.  
2) Dilute the pre-culture into 6 bottles of 1L antibiotics-supplemented LB-medium at a 
1:20 ratio. Shake at 300 rpm at 37°C. 
3) Monitor the cell density until OD600 reaches 0.6. 
4) Add 1mM IPTG to the cultures at OD600 of 0.6-0.8 to induce protein expression. 
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5) Harvest the cells after 3 hrs by centrifuging at 6,500 rpm for 15 min in a Backman 
Coulter JLA-8.1000 rotor.  
6) Discard supernatant and transfer the cell pellets into 250-ml centrifuge bottles. 
7) Cell pellets can be processed immediately for extraction of inclusion bodies, or be 
stored at -20°C for a few weeks. 
 
 
5. Preparation of inclusion bodies 
Solutions: 
Wash buffer I 
  5% (v/v) Glycerol 
  2% (v/v) Triton X-100 
50 mM Tris·Cl, pH 8.0 
  150 mM NaCl 
  1 mM EDTA 
 
 Urea solution 
50 mM Tris·Cl, pH 8.5 
  8 M Urea 
  1 mM EDTA 
  10 mM DTT 
Wash buffer II 
50 mM Tris·Cl, pH 8.0 
150 mM NaCl 





50 mM Tris·Cl, pH 8.5 
6 M Guanidine-HCl 
1 mM EDTA 
10 mM DTT 
 
Procedure (for pellet from less than 6 L culture): 
 
1) Add 100 mL pre-chilled Wash buffer I into the bottle that contains the cell pellet. 
Break the pellet using a small spoon. 
2) Sonicate the mixture for 4 minutes with the bottle in ice bath.  
Sonicator setting (Branson Sonifier 450):   
 Duty cycle – 50% 
 Output level – 7 
3) Spin down at 8,000 rpm for 10 min in a JA-14 rotor and discard supernatant 
carefully. 
4) Resuspend the pellet in 100 mL cold Wash buffer I.  
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5) Repeat steps 2), 3) and 4). 
6) Repeat step 2) and 3). 
7) Resuspend the pellet in 100 mL Wash buffer II and sonicate briefly for 2 min. 
8) Spin down at 8,000 rpm and discard supernatant. 
9) Repeat step 7). 
10) Split the 100-ml homogenized mixture into two 50-ml corning tubes.  
11) Spin down at 4,500 rpm for 30 min in a tabletop centrifuge and discard supernatant. 
12) For solubilizing MHC inclusion bodies, add 20 mL freshly made Urea solution into 
each inclusion body pellet. For solubilizing TCR, add 20 mL freshly made 
Guanidine solution into each pellet. Use 1 mL pipette tips to break the pellets for 
more efficient solubilization. 
13) Rotate the corning tubes at 4°C overnight. 
14) Clean the solubilized inclusion bodies by ultracentrifugation at 45,000 rpm for 45 
min. 
15) Store the supernatant at -80°C until ready to use.  
 
6. Purification of HLA-DR4 inclusion bodies using HQ50 column 
 
Solutions (freshly made and filtered): 
Buffer A: 20 mM Tris·Cl, pH 8.5, 8 M Urea, 1 mM DTT; 
Buffer B: 20 mM Tris·Cl, pH 8.5, 8 M Urea, 1 mM DTT, 1 M NaCl. 
Procedure: 
1) Pack 20 mL Poros HQ50 resin (Perspective Biosystems) in a XK16/20 column. 
2) Install the column onto a Biocad HPLC machine.  
3) Dilute the inclusion bodies 1:2 in buffer A.  
4) Inject 5 mL inclusion body at 2 mL/min into the HQ column each cycle.  
5) Change the flow rate to 6 mL/min and run a gradient of 0-30% buffer B over 100 
mL.  
93 
6) Collect all peaks with OD280 over 1.5 except the peak of flow through until the end 
of the gradient. 
7) Pool all collected fractions and concentrate to 1/3 of the volume at room 
temperature using an Amicon stirred cell. 
 
7. In vitro folding of proteins from solubilized inclusion bodies (large 
scale) 
 
1) Make refolding buffer without the glutathione redox pair and chill it overnight in a 
cold room. 
2) Mix the inclusion bodies of α and β chains of HLA-DR4 or MS2-3C8.  
3) Dissolve glutathione pair into the refolding buffer and stir rapidly. 
4) Add the inclusion body mixture into the refolding buffer slowly drop by drop. 
5) Keep the refolding mixture stirring in a cold room for several days (see below). 
 
7.1 Refolding of HLA-DR4 proteins including MBP/HLA-DR4, MBP–HLA-DR4 
and MBP–HLA-DR4–AviTag 
Refolding buffer 
50 mM Tris·Cl, pH 8.5 
  30% (v/v) Glycerol 
  0.5 mM EDTA 
  3 mM glutathione reduced (GSH) 
  0.9 mM glutathione oxidized (GSSG) 
 
1) Add 5 mM MBP peptide before adding inclusion bodies if refolding MBP 
non-linked HLA-DR4. 
2) Mix 20 mg/L inclusion bodies for each chain before diluting into the refolding 
buffer. 





7.2 Refolding of MS2-3C8 
Refolding buffer 
50 mM Tris·Cl, pH 9.0 
0.4 M Arginine-HCl 
0.5 mM EDTA 
3 mM glutathione reduced (GSH) 
0.9 mM glutathione oxidized (GSSG) 
 
1) Mix 25 mg/L inclusion bodies for each chain before rapid dilution.  
2) Stir at 4°C for 3 days. 
 
 
8. Quantification of small-scale refolding efficiency of MBP–HLA-
DR4 by ELISA 
For setting up small scale refolding tests, make 1 mL buffer for each condition in a 
1.5-ml microtube (Table 2.1). Add a total 40 μg of 1:1 mix of α and β inclusion bodies 
into each tube and vortex immediately. Rotate the tubes at 4°C.  
ELISA steps: 
1) Coat the capture antibody: Dilute mouse anti-DR monoclonal antibody L243 to 1 
μg/mL with PBS. Add 100 μL of diluted L243 antibody into each well of a Nunc 
MaxiSorp plate and incubate overnight at 4°C. 
2) Wash once: aspirate wells and wash once with PBS. 
3) Blocking: Add 100 μL of 2% BSA in PBS to each well and incubate at room 
temperature for 1 hour.  
4) Wash three times with PBS. 
5) Transfer 100 μL of refolding mixture 1:5 diluted with PBS from each condition to 
the wells. Incubate at room temperature for 2 hours.  
6) Wash five times with PBS plus 0.5% Tween-20.  
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7) Add 100 μL of 1:200 diluted pre-absorbed2 rabbit anti-DR sera CHAMP.  Incubate 
at room temperature for 1 hour.  
8) Wash five times with PBS plus 0.5% Tween-20. 
9) Add 100 μL of 1:10,000 diluted goat anti-rabbit IgG-HRP conjugate (Sigma) into 
each well. 
10) Wash three times with PBS plus 0.5% Tween-20. 
11) Wash three times with PBS. 
12) Add 100 μL of TMB substrate (Pierce). Keep the plate in dark and incubate at room 
temperature for 15 min.  
13) Stop reaction with 100 μL 2 M sulfuric acid.  
14) Measure OD450 for each well.  
Negative control: 
1) Replace test sample with 100 μL PBS. 
2) Replace both test sample and CHAMP with 100 μL PBS. 
 
Standard/positive controls: 
Replace test sample with 8 wells of 1:2 serially diluted HLA-DR1 at 1 μg/mL. 
 
 
9. Purification of in vitro folded proteins 
 
* The samples need to be kept cold during process.  
1) Filter the refolding mixture through filter paper. 
2) Concentrate the refolding mixture 50 times using a Sartorius concentrator with a 10-
kDa cutoff. 
3) Dialyze at least 12 hrs against 2 L 50 mM MES pH6.0 at 4°C. 
                                                        
2
 CHAMP anti-DR sera is cross-reactive to L243 mAb. To absorb the cross-reactivity, 
400 μl CHAMP was rotated overnight at 4°C with 200 μl L243-coupled agarose 
beads. The next morning spin down the beads at 3,000 rpm for 5 min. Transfer the 
supernatant of absorbed CHAMP into a new tube and supplement with 0.02% NaN3. 
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4) Remove aggregation by ultracentrifuging for 30 min at 20,000 rpm using a JA-25.5 
rotor.  
5) Concentrate to 4 mL using Amicon centrifugal filter units (Millipore). 
6) Clear the solution by spinning for 10 min at 14,000 rpm followed by filtering 
through 0.22 μM membranes.  
7) Run gel filtration with Superdex 200 column on a FPLC system. Inject 0.5-1 mL of 
sample each time. Run with PBS at a flow rate of 0.5 mL/min. Collect the peak 
around 14- to 17-ml elution volume. 
8) Pool all collected fractions and dilute 1:2 with 50 mM Tris·Cl, pH 8.0. 
9) Run anion exchange with MonoQ column. Inject 5 mL each time. Run with 50 mM 
Tris·Cl, pH 8.0 at a flow rate of 1 mL/min. Use a NaCl gradient of 1%-per-ml 
increase to elute the proteins. Collect peaks according to Figure 2.4-B and Figure 
2.5-B. 
10) Concentrate the purified proteins to at least 1 mg/mL. Aliquot and flash-freeze using 
liquid nitrogen. Store at -80°C. 
 
 
10. Biotinylation and purification of MBP–HLA-DR4–AviTag 
Reagents: 
Biotin protein ligase at 1 mg/mL purchased from Avidity, LLC 
Supplied solutions:  
10x Biomix A 
10x Biomix B 
0.5 mM Biotin 
 
1) Dialyze the purified MBP–HLA-DR4–AviTag overnight against 20 mM Tris·Cl, pH 
8.0 at 4°C. 
2) Adjust the concentration to 40 μM, i.e. about 2 mg/mL and measure the volume of 
the protein solution. 
3) Add 1/7 volume of Biomix A, 1/7 volume of Biomix B and 1/7 volume of biotin 
(0.5 mM). 
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4) For every mg of MBP–HLA-DR4–AviTag, add 5 μL of BirA biotin ligase (1 
mg/mL). 
5) Incubate 45 min at 30°C. 
6) Remove the enzyme and excess biotin by running the reaction mix through a 
Superdex 200 column. 
7) Collect the fraction. Store in -80°C freezer.  
 
11. Sedimentation velocity analysis of MS2-3C8 
The analytical ultracentrifuge used is Beckman Optima XL-A, which monitors the 
absorbance change of analyzed samples. To correlate the absorbance and the distribution 
of molecules in the solution, we prepared three concentrations of MS2-3C8: 0.2 mg/mL, 
0.4 mg/mL and 0.7 mg/mL. All samples were analyzed by their OD280. 
 
1) Dialyze 0.5 mL MS2-3C8 at 2 mg/mL against 1 L PBS for 24 hours. 
2) Filter the dialysis buffer after washing the filter membrane with the buffer three 
times. Use the filtered dialysis buffer as test blank and for diluting the protein 
samples to the three tested concentrations.  
3) Assemble three analytical cells with double-sector centerpieces as instructed. The 
cells are numbered 1 to 3, which fits into the correspondently numbered spaces on 
the rotor. 
4) Fill the reference sectors of the three cells (left with the screw-ring end facing 
toward you) with 420 μL PBS using 200 μL long micropipette tips.  
5) Fill the right sample sectors respectively with 400 μL three concentrations of MS2-
3C8 samples. 
6) Place a new red plug gasket on each filling hole and seal the holes by screwing the 
housing plugs in. Do not tighten them too much. Otherwise, you may risk distorting 
the analytical cells and break the housing plugs that are made of metal a bit soft. 
7) Weigh the assembled cells. The sample cells should be within 0.5 gram of each 
other. Otherwise, check the volumes in the sectors. Weigh the counterbalance that is 
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going to be placed opposite to cell #2. Use the weights to adjust the counterbalance 
so that its weight is equal to or within 0.5 gram less than cell #2. 
8) Load the counterbalance in cell hole 4 of an An-55 rotor and the other three 
assembled cells to position 1 to 3. Match the scribe lines on the cells with those on 
the rotor. 
9) Power on the machine and open the program. 
10) Insert the rotor into the ultracentrifuge and mount the optical arm. Close the 
chamber door. 
11) Switch on the vacuum and set temperature to 20°C. Watch the pressure drop until it 
is below 100 microns. Let the temperature equilibrate for at least an hour. 
12) Start running at 50,000 rpm at 20°C. Collect OD280 scan data from 6.0 to 7.2 cm of 
radial distance. Only 1 replicate will be recorded. Set the acceleration speed to 
maximum.  
13) Stop the run after 4 hours because the boundary has completely moved to the 
bottom of the cells. 
14) A total of 68 scans were collected for each concentration of MS2-3C8. 
15) Data process was performed using SEDFIT3. Figure 2.6 shows the fitting of cell #2 
which contains 0.4 mg/mL MS2-3C8. Global fitting of all three data sets gave the 
sedimentation coefficient of 3.8 S and 48.4 kDa, which are obtained with parameter 
settings for solvent density (ρ = 1.005 mg/mL), viscosity (η = 0.0102 Poise) and 
partial specific volume of the protein (ν = 0.73 mL/mg).  
 
 




50 mM HEPES, pH7.4 
                                                        
3 Lebowitz, J., M.S. Lewis, and P. Schuck. 2002. Modern analytical ultracentrifugation in 
protein science: a tutorial review. Protein Sci. 11:2067-2079. 
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150 mM NaCl 
0.05% Surfactant P-20 
 
1) Insert a CM5 Biacore sensor chip into the chip cassette. 
2) Prime the system with the running buffer HBSP. 
3) Set system temperature to 25°C. 
4) Immobilization of Streptavidin: Dilute 1 mg/mL Streptavidin to 0.1 mg/mL using 10 
mM NaAc, pH4.5. Open the pre-programmed amine coupling method in Biacore 
T100 control software for immobilization of streptavidin. Use a contact time of 360 
s to have over 3,000-RU incorporation. This step was applied to flow cell 1 and 2. 
Flow cell 1would serve as blank control, whereas flow cell 2 is the experimental 
one. 
5) Capture of MBP–HLA-DR4: Inject 2 μg/mL biotinylated MBP–HLA-DR4–AviTag 
for 15 s in flow cell 2. This will result in 400 to 500 RU of MBP–HLA-DR4 being 
captured onto the chip surface. 
6) Block the chip surface by injecting 20 μM biotin for 30 s for both flow cell 1 and 
flow cell 2. 
7) Inject of analyte MS2-3C8: Set flow rate at 10 μL/min. For a binding cycle of 
kinetics measurement, inject a concentration of MS2-3c8 for 60 s; for equilibrium 
measurement, inject for 240 s. Dissociation length is set to 600 s. The highest 
concentration should be about 10 times of the estimated KD. For a precise 
equilibrium measurement, use 8 times of the KD value as the highest concentration. 
Do 1:2 serial dilutions with HBSP for 6 more concentrations. The overall range for 
tested concentrations is within one-eighth to 8 times of KD . 
8) Global fitting of the kinetics data was performed using the software BiaEvaluation 
4.0 using a 1:1 binding model. The equilibrium RU was read directly from 
sensorgrams. Data fitting of the equilibrium data was done with the software 




13. Protein analysis  
 
13.1 Mass spectrometry to confirm size of the purified protein 
Matrix solution:  
20 mg/mL sinapinic acid 
50% Acetonitrile 
0.1% Trifluoroacetic acid 
Mix well and store in aliquots at -20°C  
1) Mix 1 μL protein sample and 1 μL matrix solution on a 100-well sample plate. The 
protein solution should be at 1 mg/mL and have very low ionic concentration. 
2) Put the sample plate at 37°C to allow the drop dry faster.  
3) Insert the plate into the mass spectrometer and acquire data.  
4) Compare the mass spec peak position with the theoretical molecular weight of the 
tested protein. 
 
13.2 SDS-PAGE using PhastSystem to check the purity of protein samples 
 
1) Prepare non-reduced samples by mixing 2 μL protein and 2 μL 2× Laemmli sample 
buffer. For preparing reduced samples, add an extra 0.5 μL 1 M DTT.  
2) Heat samples at 100°C for 5 min. 
3) Carefully load 4 μL sample into each well of the sample applicator.  
4) Set up a 20% homogeneous PhastGel on the PhastSystem unit. Insert the buffer 
strips. Slide in the sample applicator. 
5) Close the lid and run the preset program for 20% PhastGel. 
 
 
Ethanol-based fast coomassie staining: 
Coomassie blue stain 
50% Ethanol 50 mL 
0.25% Coomassie R250 0.31 g 
40% H2O 40 mL  Total 
10% Acetic acid 10 mL  100 mL 
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50% Ethanol 250 mL 
7% Acetic acid 35 mL  Total 
43% H2O 215 mL  500 mL 
 
Stain/Destain solution 
5% Ethanol 25 mL 
7.5% Acetic acid 37.5 mL  Total 
87.5% H2O 447.5 mL  500 mL 
 
Preserving solution 
5% Glycerol 50 mL 
10% Acetate acid 100 mL  Total 
85% H2O 850 mL  1 L 
 
1) Make the staining solution by adding 1 mL Coomassie blue stain into 100 mL 
Stain/Destain solution.  
2) Add 100 mL fix solution to cover gel. 
3) Microwave both for 1 min. 
4) Transfer the gel into the staining solution and put on a rocking shelf. 
5) Bands can be seen after 10 min and will become darker if continuing staining. 
6) Destain if needed with the Stain/Destain solution. Or directly transfer into 
preserving solution for destaining and preserving. 
 
13.3 UV spectrometry to determine protein concentration 
 
1) Use the buffer of the protein solution as blank.  
2) Dilute protein samples X times with the same buffer until the measured A280 is in 
the range of 0.1 to 1.  
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3) Check the value of absorbance parameters for each protein (see Appendix.1) and 
calculate the concentration of the protein in mg/mL or μM using the following two 
equations: 
[protein] (mg/mL) = A280 × X × (mg/mL per OD280) 
[protein] (μM) = A280 × X ×106 ÷ Extinction Coefficient 
UV spectrometry is not ideal for precise determination of the absolute 
concentration of a protein sample. But it is probably the most convenient method. If 
done carefully, the reproducibility, one of the most important issues for crystallization, 
should be acceptable. 
 
14. Co-crystallization of MS2-3C8 and MBP–HLA-DR4 
 
1) Dialyze overnight both MS2-3C8 and MBP–HLA-DR4 against 10 mM Tris·Cl, pH 
8.0, 5 mM NaCl at 4°C. 
2) Concentrate both proteins to 10 mg/mL. 
3) Mix 50 μL MS2-3C8 and 46 μL MBP–HLA-DR4 for 1:1 molar ratio. The ratio can 
be roughly checked by SDS-PAGE. 
4) Set up hanging-drop crystallization using the available commercial crystal screening 
kits, including Crystal Screen I (Hampton Research), II and Lite, Wizard I and II 
(Emerald Biosystems), etc. Briefly, add 480 μL of each crystallization solution into 
a well of a crystallization plate. Pipette 0.5 μL of the crystallization solution to the 
cover slip. Add 0.5 μL protein mixture into the drop.  
5) Seal the wells using the cover slips with the crystallization drop facing downwards.  
6) Put the crystal plates at room temperature in a dark and disturbance-free place. 
7) Look for crystals in each crystallization drop under a microscope after 2 days.  
 
 
15. Optimization of crystallization conditions and seeding  
Initial crystal screen gave three hits with PEG as precipitants: Crystal screen I #14, 
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Crystal screen lite #17and Wizard I #46. The crystals are all in the form of small needles. 
Trying to optimize the crystals, a 3x4-well matrix was made for each condition, which 
included either modified PEG concentration or modified pH. The volume used for 
optimization was doubled as 1 μL crystallization solution plus 1μL protein. One condition 
modified from Wizard I #46 grew small plates, whereas other conditions did not support 
crystal formation or still grew crystal needles. The new condition was 1 mL protein 
solution and 1 mL 10% (w/v) polyethylene glycol 8000, 0.2 M calcium acetate, and 0.1 
M imidazole (pH 8.5) (solution M). This condition was repeated, but not every drop 
could yield crystals. This may indicate that the nucleation step of crystal growth could 
have some difficulty. 
Therefore, crystal seeding was used to deliver pre-formed crystal nuclei that may 
help grow bigger crystals. In addition, to control the evaporation rate during crystal 
growth, the well solutions were replaced by crystal screen #6 (we have a bulk stock.) plus 
different amount of water. Briefly, there are several steps to perform a seeding experiment. 
 
1) Mix crystal screen #6 with 0, 50, 100, 150, 200, 250, 300, 350, 400 μL ddH2O to 
make a total 500 μL well solution.  
2) Set up crystallization drop by mixing 1 μL MS2-3C8/MBP–DR4 protein mixture 
and 1 μL solution M. 
3) Equilibrate for 6 hours before start of seeding. 
4) Make the wash solution by mixing 2 parts of water and 3 parts of solution M. 
5) Pipette 2 drops of 1 μL wash solution on a single cover slip. 
6) Transfer a crystal plate from the crystallization drop to one of the wash drops using 
a 0.05-mm crystal loop. 
7) Shake the crystal in the drop a few times and transfer the crystal plate to the other 
drop. 
8) Break the crystal into tiny pieces with the loop. 
9) Pick up a loop of solution containing the crystal seeds (you may not see it, but it is 
there) and transfer it to each equilibrated crystallization drop. 
10) Check for crystals the next morning. 
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The well solution with 150 μL gave the biggest crystals. The same seeding 




16. Flash freezing and storage of protein crystals 
 
1) Make 500 μL of cryoprotectant solution that contains all the ingredients of solution 
M plus 20% glycerol.  
2) Fill a cylindrical dewar (Pope scientific, height: 337 mm) with liquid nitrogen (LN). 
Slowly immerse a CryoCane (Hampton research) in LN.  
3) Place a cryo vial in the vial clamp and set aside.  
4) Select a CrystalCap mounted with a CryoLoop that fits the size of the crystal to be 
frozen. 
5) Put the CrystalCap on a CrystalWand. 
6) Pipette 2 drops of 1 μL cryo-solution on a clean cover slip. 
7) Manipulate the CrystalWand to pick up a single crystal and wash quickly through 
two cryo drops. 
8) Immerse the crystal in LN. 
9) Use the other hand to handle the clamp and immerse the cryo vial. 
10) Slowly slide the crystal into the vial until the CrystalCap locks in the vial. 
11) Transfer the vial from the clamp onto the CryoCane. Always put from the bottom of 
the cane. 
12) Fill all the spaces on a CryoCane except the top one. Immerse a CryoSleeve in LN. 
Insert the cane in the sleeve. 
13) Transfer the sleeved cane into a big LN tank for storage. 
 
 
17. X-ray data collection and process 
X-ray diffraction can be done with an in-house X-ray source or by sending the frozen 
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crystals to a synchrotron. To send the crystals for remote collection, make sure that the 
nitrogen dry shipper works well before putting in the crystals. 
For in-house collection, there is no need to pre-freeze the crystals. Simply mount the 
crystal on the goniometer after two washes. Adjust the position of the crystal so that it is 
centered at the X-ray beam. Set the goniometer to 0 degree and lock. 
For initial screening, set the crystal-to-detector distance to 200 mm. Collect 5 or 10 
min exposure data for both 0 and 90 degrees. In-house diffraction of MS2-3C8 complex 
crystals can reach about 3.2 Å. Index gave the space group of P43212 and cell parameters.  
For an in-house data collection, each image was collected from 30-min exposure. A 
total180° dataset was collected with 0.5° steps.  
Frozen crystals were also sent to National Synchrotron Light Sourse in Brookhave 
National Laboraotry, the best of which diffracted to 2.8 Å with a 1.075 Å X-ray beam. 
The diffraction quality of synchrotron light was much better than in-house collection, 
since both the wavelength and intensity of X-ray was more advanced. At NSLS, a 
complete 360° data set was collected with 1° steps.  






18. Molecular replacement 
Data truncation was performed using old truncation program in CCP4 suite. 
Molecular replacement (MR) was done with reflections lower than 3.5 Å using the 
program Phaser5. Details of the searching steps were described in chapter 4.2. A correct 




                                                        
4
 Otwinowski, Z., and W. Minor. 1997. Processing of X-ray Diffraction Data Collected in 
Oscillation Mode. Methods in Enzymology. 276:307-326. 
5
 Storoni, L.C., A.J. McCoy, and R.J. Read. 2004. Likelihood-enhanced fast rotation 
functions. Acta Crystallogr D Biol Crystallogr. 60:432-438. 
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19. Structure refinement and manual model fitting 
After two MS2-3C8 complexes were correctly placed in the asymmetric unit, rigid 
body refinement was completed with the program CNS6. 5% of the reflections were 
assigned to the test set. The first 2Fo-Fc and Fo-Fc electron density maps were also 
generated by CNS. The two maps were loaded into the model-building program Coot7. It 
was shown that the CDR loops were not fit well into the densities due to the difference 
from the MR model. In addition, clear electron density was shown at the linker region in 
one of the MS2-3C8 complexes. The model was manually adjusted to fit the electron 
densities. Later structure refinement and map calculation was performed with the 
program Phenix8. Model fitting was constantly monitored by Rwork and Rfree values. Water 
molecules were added using a cutoff distance of 3.4 Å and only added at the positions 
with unambiguous electron densities. Some loops that are distant from the binding 
interface did not show densities. The amino acid residues for those regions were omitted 
from the model. To validate the structure model, deviated atom positions were corrected 
as far as they agreed with the electron densities. The final step of refinement gave the 
Rwork of 23.9% and Rfree of 27.9%. An optional TLS
9 refinement was also performed 
using Phenix, which resulted a further drop for both Rwork (22.2%) and Rfree (26.3%) 
values.  
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20. Structure analysis and figure preparation 
 
Solvent-accessible surface areas were calculated using the program AREAIMOL 
(Collaborative Computational Project No. 4, 1994) with a probe radius of 1.4 Ǻ. Contacts 
were identified by CONTACT using a cut-off distance of 4.0 Å. All structure figures 
were prepared using PyMOL 10 , a feasible whereas powerful and versatile molecular 
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